id pmid doi document_id type authors title isbn10 url journal volume issue dp_year pages 2885 13679426 10.1523/JNEUROSCI.23-24-08568.2003 JOURNAL ARTICLE Chen M, Dong Y, Simard JM Functional coupling between sulfonylurea receptor type 1 and a nonselective cation channel in reactive astrocytes from adult rat brain J Neurosci 23 24 2003 8568–8577 2886 10064839 10.1016/s0006-8993(99)01125-7 JOURNAL ARTICLE Chou YC, Liao JF, Chang WY, Lin MF, Chen CF Binding of dimemorfan to sigma-1 receptor and its anticonvulsant and locomotor effects in mice, compared with dextromethorphan and dextrorphan Brain Res 821 2 1999 516-519 2897 21818695 10.1208/s12248-011-9290-9 JOURNAL ARTICLE Benet LZ, Broccatelli F, Oprea TI BDDCS applied to over 900 drugs https://link.springer.com/content/pdf/10.1208/s12248-011-9290-9.pdf The AAPS journal 13 4 2011 "519-547 " 2898 15546675 10.1016/j.yrtph.2004.08.004 JOURNAL ARTICLE Contrera JF, Matthews EJ, Kruhlak NL, Benz RD Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose https://www.sciencedirect.com/science/article/abs/pii/S0273230004001138 Regul Toxicol Pharmacol 40 3 2004 "185-206 " 2899 26589308 10.1208/s12248-015-9845-2 JOURNAL ARTICLE Hosey CM, Chan R, Benet LZ BDDCS predictions, self-correcting aspects of BDDCS assignments, BDDCS assignment corrections, and classification for more than 175 additional drugs https://link.springer.com/content/pdf/10.1208/s12248-015-9845-2.pdf The AAPS journal 18 1 2016 "251-260 " 2900 24306326 10.1007/s11095-013-1222-1 JOURNAL ARTICLE Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches https://link.springer.com/content/pdf/10.1007/s11095-013-1222-1.pdf Pharm Res 31 4 2014 "1002-1014 " 2901 30115648 10.1124/dmd.118.082966 JOURNAL ARTICLE Lombardo F, Berellini G, Obach RS Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds https://dmd.aspetjournals.org/content/dmd/46/11/1466.full.pdf Drug Metab Dispos 46 11 2018 1466-1477 2902 BLA:761115 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/761115Orig1s000MultidisciplineR.pdf 2020 2903 NDA:213591 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213591s000lbl.pdf 2020 2904 21918175 10.1158/1078-0432.CCR-11-1157 JOURNAL ARTICLE Liu X, Wang Q, Yang G, Marando C, Koblish HK, Hall LM, Fridman JS, Behshad E, Wynn R, Li Y, Boer J, Diamond S, He C, Xu M, Zhuo J, Yao W, Newton RC, Scherle PA A novel kinase inhibitor, INCB28060, blocks c-MET-dependent signaling, neoplastic activities, and cross-talk with EGFR and HER-3 Clin Cancer Res 17 22 2011 7127-7138 2905 NDA:213246 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213246s000lbl.pdf 2020 2907 NDA:213246 review DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213246Orig1s000MultidisciplineR.pdf 2020 2908 NDA:213973 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213973s000lbl.pdf 2020 2909 31085175 10.1016/j.ccell.2019.04.006 JOURNAL ARTICLE Smith BD, Kaufman MD, Lu WP, Gupta A, Leary CB, Wise SC, Rutkoski TJ, Ahn YM, Al-Ani G, Bulfer SL, Caldwell TM, Chun L, Ensinger CL, Hood MM, McKinley A, Patt WC, Ruiz-Soto R, Su Y, Telikepalli H, Town A, Turner BA, Vogeti L, Vogeti S, Yates K, Janku F, Abdul Razak AR, Rosen O, Heinrich MC, Flynn DL Ripretinib (DCC-2618) is a switch control kinase inhibitor of a broad spectrum of oncogenic and drug-resistant KIT and PDGFRA variants Cancer Cell 35 5 2019 738-751 2910 NDA:212155 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212155s000lbl.pdf 2020 2911 NDA:212123 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212123s000lbl.pdf 2020 2912 BLA:761142 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761142s000lbl.pdf 2020 2913 NDA:213702 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213702s000lbl.pdf 2020 2914 NDA:212295 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212295s000lbl.pdf 2020 2915 17585216 10.1097/01.anes.0000267503.85085.c0 JOURNAL ARTICLE Kilpatrick GJ, McIntyre MS, Cox RF, Stafford JA, Pacofsky GJ, Lovell GG, Wiard RP, Feldman PL, Collins H, Waszczak BL, Tilbrook GS CNS 7056: a novel ultra-short-acting benzodiazepine Anesthesiology 107 1 2007 60-66 2916 22547625 10.1128/AAC.00426-12 JOURNAL ARTICLE Nowicka-Sans B, Gong YF, McAuliffe B, Dicker I, Ho HT, Zhou N, Eggers B, Lin PF, Ray N, Wind-Rotolo M, Zhu L, Majumdar A, Stock D, Lataillade M, Hanna GJ, Matiskella JD, Ueda Y, Wang T, Kadow JF, Meanwell NA, Krystal M In vitro antiviral characteristics of HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068 Antimicrob Agents Chemother 56 7 2012 3498–3507 2917 NDA:212950 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212950s000lbl.pdf 2020 2918 NDA:212576 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212576s000lbl.pdf 2020 2919 24520856 10.1021/jm401856k JOURNAL ARTICLE Ferraris D, Duvall B, Delahanty G, Mistry B, Alt J, Rojas C, Rowbottom C, Sanders K, Schuck E, Huang KC, Redkar S, Slusher BB, Tsukamoto T Design, synthesis, and pharmacological evaluation of fluorinated tetrahydrouridine derivatives as inhibitors of cytidine deaminase J Med Chem 57 6 2014 2582–2588 2920 BLA:761163 review DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/761163Orig1s000MultidisciplineR.pdf 2020 2921 BLA:761163 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761163s000lbl.pdf 2020 2922 BLA:761158 review DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/761158Orig1s000MultidisciplineR.pdf 2020 2923 BLA:761158 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761158s000lbl.pdf 2020 2924 32936437 10.1007/s40265-020-01404-x JOURNAL ARTICLE Markham A Belantamab Mafodotin: First Approval Drugs 80 15 2020 1607-1613 2925 NDA:210730 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210730s000lbl.pdf 2020 2926 23300227 10.1124/jpet.112.201616 JOURNAL ARTICLE DeWire SM, Yamashita DS, Rominger DH, Liu G, Cowan CL, Graczyk TM, Chen XT, Pitis PM, Gotchev D, Yuan C, Koblish M, Lark MW, Violin JD A G protein-biased ligand at the mu-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine J Pharmacol Exp Ther 344 3 2013 708-717 2927 BLA:212154 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212154Orig1s000lbl.pdf 2020 2928 BLA:212154 review DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212154Orig1s000PharmR.pdf 2020 2929 BLA:761149 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761149s000lbl.pdf 2020 2930 BLA:761149 review DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/761149Orig1s000PharmR.pdf 2020 2931 NDA:213433 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213433s000lbl.pdf 2020 2933 NDA:213227 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213227s000lbl.pdf 2020 2934 29668724 10.1371/journal.pone.0195802 JOURNAL ARTICLE Rylova SN, Stoykow C, Del Pozzo L, Abiraj K, Tamma ML, Kiefer Y, Fani M, Maecke HR The somatostatin receptor 2 antagonist 64Cu-NODAGA-JR11 outperforms 64Cu-DOTA-TATE in a mouse xenograft mod PLoS One 13 4 2018 e0195802 2935 NDA:213721 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213721s000lbl.pdf 2020 2936 29657135 10.1158/2159-8290.CD-18-0338 JOURNAL ARTICLE Subbiah V, Gainor JF, Rahal R, Brubaker JD, Kim JL, Maynard M, Hu W, Cao Q, Sheets MP, Wilson D, Wilson KJ, DiPietro L, Fleming P, Palmer M, Hu MI, Wirth L, Brose MS, Ou SI, Taylor M, Garralda E, Miller S, Wolf B, Lengauer C, Guzi T, Evans EK Precision targeted therapy with BLU-667 for RET-driven cancers Cancer Discov 8 7 2018 836-849 2937 NDA:214787 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214787Orig1s000lbl.pdf 2020 2938 32668216 10.1016/j.celrep.2020.107940 JOURNAL ARTICLE Pruijssers AJ, George AS, Schafer A, Leist SR, Gralinksi LE, Dinnon KH 3rd, Yount BL, Agostini ML, Stevens LJ, Chappell JD, Lu X, Hughes TM, Gully K, Martinez DR, Brown AJ, Graham RL, Perry JK, Du Pont V, Pitts J, Ma B, Babusis D, Murakami E, Feng JY, Bilello JP, Porter DP, Cihlar T, Baric RS, Denison MR, Sheahan TP Remdesivir inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice Cell Rep 32 3 2020 107940 2939 BLA:761156 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761156s000lbl.pdf 2020 2940 32053994 10.3390/ijms21041181 JOURNAL ARTICLE Petersen M, Gandhi PS, Buchardt J, Alanentalo T, Fels JJ, Johansen NL, Helding-Kvist P, Vad K, Thygesen P Tissue distribution and receptor activation by somapacitan, a long acting growth hormone derivative Int J Mol Sci 21 4 2020 1181 2941 NDA:213969 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213969s000lbl.pdf 2020 2942 10377218 10.1021/jm990030g JOURNAL ARTICLE Strickland CL, Weber PC, Windsor WT, Wu Z, Le HV, Albanese MM, Alvarez CS, Cesarz D, del Rosario J, Deskus J, Mallams AK, Njoroge FG, Piwinski JJ, Remiszewski S, Rossman RR, Taveras AG, Vibulbhan B, Doll RJ, Girijavallabhan VM, Ganguly AK Tricyclic farnesyl protein transferase inhibitors: crystallographic and calorimetric studies of structure−activity relationships J Med Chem 42 12 1999 2125–2135 2943 NDA:213793 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213793Orig1s000RPLlbl.pdf 2020 2944 NDA:213793 review DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213793Orig1s000ClinPharmR.pdf 2020 3043 EMEA/H/C/004854 DRUG LABEL https://www.ema.europa.eu/en/documents/product-information/hepcludex-epar-product-information_en.pdf 2020 3045 33058042 10.1007/s40265-020-01418-5 JOURNAL ARTICLE Al-Salama ZT Imlifidase: first approval Drugs 80 17 2020 1859-1864 3046 EMEA/H/C/005113 DRUG LABEL https://www.ema.europa.eu/en/documents/product-information/jyseleca-epar-product-information_en.pdf 2020 3047 24006460 10.4049/jimmunol.1201348 JOURNAL ARTICLE Van Rompaey L, Galien R, van der Aar EM, Clement-Lacroix P, Nelles L, Smets B, Lepescheux L, Christophe T, Conrath K, Vandeghinste N, Vayssiere B, De Vos S, Fletcher S, Brys R, van't Klooster G, Feyen JH, Menet C Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases J Immunol 191 7 2013 3568-3577 3048 32852744 10.1007/s40265-020-01383-z JOURNAL ARTICLE Markham A Vadadustat: first approval Drugs 80 13 2020 1365-1371 3049 32880805 10.1007/s40265-020-01384-y JOURNAL ARTICLE Dhillon S Daprodustat: first approval Drugs 80 14 2020 1491-1497 3050 28928122 10.1124/jpet.117.242503 JOURNAL ARTICLE Ariazi JL, Duffy KJ, Adams DF, Fitch DM, Luo L, Pappalardi M, Biju M, DiFilippo EH, Shaw T, Wiggall K, Erickson-Miller C Discovery and preclinical characterization of GSK1278863 (daprodustat), a small molecule hypoxia inducible factor-prolyl hydroxylase inhibitor for anemia J Pharmacol Exp Ther 363 3 2017 336-347 3051 31953125 10.1016/j.bbagen.2020.129531 JOURNAL ARTICLE Liclican A, Serafini L, Xing W, Czerwieniec G, Steiner B, Wang T, Brendza KM, Lutz JD, Keegan KS, Ray AS, Schultz BE, Sakowicz R, Feng JY Biochemical characterization of tirabrutinib and other irreversible inhibitors of Bruton's tyrosine kinase reveals differences in on - and off - target inhibition Biochim Biophys Acta Gen Subj 1864 4 2020 129531 3052 32361823 10.1007/s40265-020-01317-9 JOURNAL ARTICLE Markham A Tepotinib: first approval Drugs 80 8 2020 829-833 3053 23553846 10.1158/1078-0432.CCR-12-3247 JOURNAL ARTICLE Bladt F, Faden B, Friese-Hamim M, Knuehl C, Wilm C, Fittschen C, Gradler U, Meyring M, Dorsch D, Jaehrling F, Pehl U, Stieber F, Schadt O, Blaukat A EMD 1214063 and EMD 1204831 constitute a new class of potent and highly selective c-Met inhibitors Clin Cancer Res 19 11 2013 2941-2951 3054 31371478 10.1124/jpet.119.259341 JOURNAL ARTICLE Taniguchi T, Ashizawa N, Matsumoto K, Saito R, Motoki K, Sakai M, Chikamatsu N, Hagihara C, Hashiba M, Iwanaga T Pharmacological evaluation of dotinurad, a selective urate reabsorption inhibitor J Pharmacol Exp Ther 371 1 2019 162-170 3056 33062187 10.1021/acsmedchemlett.0c00176 JOURNAL ARTICLE Uda J, Kobashi S, Miyata S, Ashizawa N, Matsumoto K, Iwanaga T Discovery of dotinurad (FYU-981), a new phenol derivative with highly potent uric acid lowering activity ACS Med Chem Lett 11 10 2020 2017-2023 3057 25387665 10.1007/s00011-014-0782-9 JOURNAL ARTICLE Tanimoto A, Ogawa Y, Oki C, Kimoto Y, Nozawa K, Amano W, Noji S, Shiozaki M, Matsuo A, Shinozaki Y, Matsushita M Pharmacological properties of JTE-052: a novel potent JAK inhibitor that suppresses various inflammatory responses in vitro and in vivo Inflamm Res 64 1 2015 41-51 3058 31301309 10.1016/j.ejphar.2019.172532 JOURNAL ARTICLE Fukui K, Shinozaki Y, Kobayashi H, Deai K, Yoshiuchi H, Matsui T, Matsuo A, Matsushita M, Tanaka T, Nangaku M JTZ-951 (enarodustat), a hypoxia-inducibe factor prolyl hydroxylase inhibitor, stabilizes HIF-α protein and induces erythropoiesis without effects on the function of vascular endothelial growth factor Eur J Pharmacol 15 859 2019 172532 3059 33320297 10.1007/s40265-020-01444-3 JOURNAL ARTICLE Markham A Enarodustat: first approval Drugs 2020 3060 33236266 10.1007/s40265-020-01438-1 JOURNAL ARTICLE Paik J Sofpironium Bromide: first approval Drugs 80 18 2020 1981-1986 3061 NDA:212642 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212642s000lbl.pdf 2020 3062 29619657 10.1186/s13550-018-0378-4 JOURNAL ARTICLE Sanchez-Crespo A, Jussing E, Björklund AC, Pokrovskaja Tamm K Hallmarks in prostate cancer imaging with Ga68-PSMA-11-PET/CT with reference to detection limits and quantitative properties EJNMMI Res 8 1 2018 27 3063 NDA:214094 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214094s000lbl.pdf 2020 3066 NDA:214094 review DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214094Orig1s000MultidisciplineR.pdf 2020 3068 NDA:214621 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214621s000lbl.pdf 2020 3069 30937733 10.1007/s40265-019-01105-0 JOURNAL ARTICLE Markham A Relugolix: first global approval Drugs 79 6 2019 675–679 3070 BLA:761172 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761172s000lbl.pdf 2020 3071 BLA:761150 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761150s000lbl.pdf 2020 3073 BLA:761171 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761171lbl.pdf 2020 3074 BLA:761171 review DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/761171Orig1s000MultidisciplineR.pdf 2020 3075 BLA:761169 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761169s000lbl.pdf 2020 3077 NDA:213973 review DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213973Orig1s000MultidisciplineR.pdf 2020 3078 20605905 10.1124/jpet.110.168062 JOURNAL ARTICLE Herbst R, Wang Y, Gallagher S, Mittereder N, Kuta E, Damschroder M, Woods R, Rowe DC, Cheng L, Cook K, Evans K, Sims GP, Pfarr DS, Bowen MA, Dall'Acqua W, Shlomchik M, Tedder TF, Kiener P, Jallal B, Wu H, Coyle AJ B-cell depletion in vitro and in vivo with an afucosylated anti-CD19 antibody J Pharmacol Exp Ther 335 1 2010 213-222 3079 NDA:210730 review DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/210730Orig1s000MultidisciplineR.pdf 2020 3080 NDA:213433 review DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213433Orig1s000MultidisciplineR.pdf 2020 3081 NDA:213721 review DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213721Orig1s000MultidisciplineR.pdf 2020 2750 31132753 10.1016/j.phymed.2019.152956 JOURNAL ARTICLE Bailly C Cepharanthine: An update of its mode of action, pharmacological properties and medical applications Phytomedicine 62 2019 152956 2751 32149769 10.1097/CM9.0000000000000797 JOURNAL ARTICLE Fan HH, Wang LQ, Liu WL, An XP, Liu ZD, He XQ, Song LH, Tong YG Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus (2019-nCoV) related coronavirus model Chin Med J 2020 2752 10.26434/chemrxiv.12039888.v1 JOURNAL ARTICLE Xu Z, Yao H, Shen J, Wu N, Xu Y, Lu X Nelfinavir is active against SARS-CoV-2 in Vero E6 cells ChemRxiv 2020 2753 32251768 10.1016/j.antiviral.2020.104787 JOURNAL ARTICLE Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM The FDA-approved drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro Antiviral Res 2020 2754 10.1101/2020.03.20.999730 JOURNAL ARTICLE Jeon S, Ko M, Lee J, Choi I, Byun SY, Park S, Shum D, Kim S Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs bioRxiv 2020 2755 10.1101/2020.04.03.023846 JOURNAL ARTICLE Touret F, Gilles M, Barral K, Nougairede A, Decroly E, de Lamballerie X, Coutard B In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication bioRxiv 2020 2756 32194981 10.1038/s41421-020-0156-0 JOURNAL ARTICLE Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H, Li Y, Hu Z, Zhong W, Wang M Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro Cell Discov 6 16 2020 2757 32251767 10.1016/j.antiviral.2020.104786 JOURNAL ARTICLE Choy KT, Wong AY, Kaewpreedee P, Sia SF, Chen D, Hui KPY, Chu DKW, Chan MCW, Cheung PP, Huang X, Peiris M, Yen HL Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro Antiviral Res 178 2020 2758 32020029 10.1038/s41422-020-0282-0 JOURNAL ARTICLE Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro Cell Res 30 3 2020 269-271 2759 10.1101/2020.03.11.987016 JOURNAL ARTICLE Matsuyama S, Kawase M, Nao N, Shirato K, Ujike M, Kamitani W, Shimojima M, Fukushi S The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15 bioRxiv 2020 2760 10.1101/2020.03.23.004580 JOURNAL ARTICLE Li Z, Li X, Huang YY, Wu Y, Zhou L, Liu R, Wu D, Zhang L, Liu H, Xu X, Zhang Y, Cui J, Wang X, Luo HB FEP-based screening prompts drug repositioning against COVID-19 bioRxiv 2020 2761 10.1101/2020.02.05.935387 JOURNAL ARTICLE Zhang J, Ma X, Yu F, Liu J, Zou F, Pan T, Zhang H Teicoplanin potently blocks the cell entry of 2019-nCoV bioRxiv 2020 2762 32253226 10.1126/scitranslmed.abb5883 JOURNAL ARTICLE Sheahan TP, Sims AC, Zhou S, Graham RL, Pruijssers AJ, Agostini ML, Leist SR, Schafer A, Dinnon KH, Stevens LJ, Chappell JD, Lu X, Hughes TM, George AS, Hill CS, Montgomery SA, Brown AJ, Bluemling GR, Natchus MG, Saindane M, Kolykhalov AA, Painter G, Harcourt J, Tamin A, Thornburg NJ, Swanstrom R, Denison MR, Baric RS An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice Sci Transl Med 2020 eabb5883 2763 10.1101/2020.03.11.986836 JOURNAL ARTICLE Ge Y, Tian T, Huang S, Wan F, Li J, Li S, Yang H, Hong L, Wu N, Yuan E, Cheng L, Lei Y, Shu H, Feng X, Jiang Z, Chi Y, Guo X, Cui L, Xiao L, Li Z, Yang C, Miao Z, Tang H, Chen L, Zeng H, Zhao D, Zhu F, Shen X, Zeng J A data-driven drug repositioning framework discovered a potential therapeutic agent targeting COVID-19 bioRxiv 2020 2764 NDA:212608 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212608s000lbl.pdf 2020 2765 29093181 10.1126/scitranslmed.aao1690 JOURNAL ARTICLE Evans EK, Gardino AK, Kim JL, Hodous BL, Shutes A, Davis A, Zhu XJ, Schmidt-Kittler O, Wilson D, Wilson K, DiPietro L, Zhang Y, Brooijmans N, LaBranche TP, Wozniak A, Gebreyohannes YK, Schöffski P, Heinrich MC, DeAngelo DJ, Miller S, Wolf B, Kohl N, Guzi T, Lydon N, Boral A, Lengauer C A precision therapy against cancers driven by KIT/PDGFRA mutations Sci Transl Med 9 414 2017 eaao1690 2766 NDA:211723 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211723s000lbl.pdf 2020 2767 NDA:212728 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212728s000lbl.pdf 2020 2768 23153230 10.1021/jm3013147 JOURNAL ARTICLE Luo G, Chen L, Conway CM, Denton R, Keavy D, Signor L, Kostich W, Lentz KA, Santone KS, Schartman R, Browning M, Tong G, Houston JG, Dubowchik GM, Macor JE Discovery of (5S,6S,9R)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl 4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate (BMS-927711): an oral calcitonin gene-related peptide (CGRP) antagonist in clinical trials for treating migraine J Med Chem 55 23 2012 10644-10651 2769 NDA:211616 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211616s000lbl.pdf 2020 2770 27892461 10.1038/ncomms13457 JOURNAL ARTICLE Pinkosky SL, Newton RS, Day EA, Ford RJ, Lhotak S, Austin RC, Birch CM, Smith BK, Filippov S, Groot PHE, Steinberg GR, Lalwani ND Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis Nat Commun 7 2016 13457 2771 NDA:209899 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209899s000lbl.pdf 2020 2772 26990079 10.1111/bph.13476 JOURNAL ARTICLE Scott FL, Clemons B, Brooks J, Brahmachary E, Powell R, Dedman H, Desale HG, Timony GA, Martinborough E, Rosen H, Roberts E, Boehm MF, Peach RJ Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1) and receptor-5 (S1P5) agonist with autoimmune disease-modifying activity Br J Pharmacol 173 11 2016 1778-1792 2773 NDA:212801 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212801s000lbl.pdf 2020 2774 32141023 10.1007/s40265-020-01277-0 JOURNAL ARTICLE Duggan S Osilodrostat: First Approval Drugs 80 5 2020 495-500 2775 BLA:761113 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761113s000lbl.pdf 2020 2776 24987056 10.1158/1078-0432.CCR-14-0695 JOURNAL ARTICLE Deckert J, Wetzel MC, Bartle LM, Skaletskaya A, Goldmacher VS, Vallee F, Zhou-Liu Q, Ferrari P, Pouzieux S, Lahoute C, Dumontet C, Plesa A, Chiron M, Lejeune P, Chittenden T, Park PU, Blanc V SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies Clin Cancer Res 20 17 2014 4574-4583 2777 BLA:761119 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761119s000lbl.pdf 2020 2778 BLA:761119 review DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/761119Orig1s000OtherR.pdf 2020 2779 BLA:761143 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761143s000lbl.pdf 2020 2780 20847162 10.2967/jnumed.110.075648 JOURNAL ARTICLE Heskamp S, van Laarhoven HW, Molkenboer-Kuenen JD, Franssen GM, Versleijen-Jonkers YM, Oyen WJ, van der Graaf WT, Boerman OC ImmunoSPECT and immunoPET of IGF-1R expression with the radiolabeled antibody R1507 in a triple-negative breast cancer model J Nucl Med 51 10 2010 1565-1572 2781 17332304 10.1158/1078-0432.CCR-06-1150 JOURNAL ARTICLE Yeh TC, Marsh V, Bernat BA, Ballard J, Colwell H, Evans RJ, Parry J, Smith D, Brandhuber BJ, Gross S, Marlow A, Hurley B, Lyssikatos J, Lee PA, Winkler JD, Koch K, Wallace E Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor Clin Cancer Res 13 5 2007 1576-1583 2782 NDA:213756 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213756s000lbl.pdf 2020 2783 NDA:213411 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213411s000lbl.pdf 2020 2784 32241871 10.1158/1535-7163.MCT-19-0873 JOURNAL ARTICLE Kulukian A, Lee P, Taylor J, Rosler R, de Vries P, Watson D, Forero-Torres A, Peterson S Preclinical activity of HER2-Selective tyrosine kinase inhibitor tucatinib as a single agent or in combination with trastuzumab or docetaxel in solid tumor models Mol Cancer Ther 19 4 2020 976-987 2785 32315352 10.1371/journal.pone.0231877 JOURNAL ARTICLE Liu PCC, Koblish H, Wu L, Bowman K, Diamond S, DiMatteo D, Zhang Y, Hansbury M, Rupar M, Wen X, Collier P, Feldman P, Klabe R, Burke KA, Soloviev M, Gardiner C, He X, Volgina A, Covington M, Ruggeri B, Wynn R, Burn TC, Scherle P, Yeleswaram S, Yao W, Huber R, Hollis G INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models PLoS One 15 4 2020 e0231877 2786 NDA:213736 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213736s000lbl.pdf 2020 2883 27926532 10.18632/oncotarget.13749 JOURNAL ARTICLE He JX, Wang M, Huan XJ, Chen CH, Song SS, Wang YQ, Liao XM, Tan C, He Q, Tong LJ, Wang YT, Li XH, Su Y, Shen YY, Sun YM, Yang XY, Chen Y, Gao ZW, Chen XY, Xiong B, Lu XL, Ding J, Yang CH, Miao ZH Novel PARP1/2 inhibitor mefuparib hydrochloride elicits potent in vitro and in vivo anticancer activity, characteristic of high tissue distribution Oncotarget 8 3 2017 4156–4168 2884 26934220 10.1038/nature17180 Warren TK, Jordan R, Lo MK, Ray AS, Mackman RL, Soloveva V, Siegel D, Perron M, Bannister R, Hui HC, Larson N, Strickley R, Wells J, Stuthman KS, Van Tongeren SA, Garza NL, Donnelly G, Shurtleff AC, Retterer CJ, Gharaibeh D, Zamani R, Kenny T, Eaton BP, Grimes E, Welch LS, Gomba L, Wilhelmsen CL, Nichols DK, Nuss JE, Nagle ER, Kugelman JR, Palacios G, Doerffler E, Neville S, Carra E, Clarke MO, Zhang L, Lew W, Ross B, Wang Q, Chun K, Wolfe L, Babusis D, Park Y, Stray KM, Trancheva I, Feng JY, Barauskas O, Xu Y, Wong P, Braun MR5, Flint M, McMullan LK, Chen SS, Fearns R5, Swaminathan S, Mayers DL, Spiropoulou CF, Lee WA, Nichol ST, Cihlar T, Bavari S Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys Nature 531 7594 2016 381–385 2004 10.1016/S0016-5085(10)61017-7 JOURNAL ARTICLE Gillberg, Per-Göran; Dahlström, Mikael; AU - Starke, Ingemar; Östlund-Lindqvist, Ann-Margret S1301 The IBAT Inhibition by A3309 - A Potential Mechanism for the Treatment of Constipation http://dx.doi.org/10.1016/S0016-5085(10)61017-7 Gastroenterology 138 5 2010 S-224 2005 NDA:210491 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210491lbl.pdf 2018 2006 NDA:208700 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208700s000lbl.pdf 2018 2007 NDA:205598 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/205598s000lbl.pdf 2017 2008 12240910 JOURNAL ARTICLE Broglio F, Boutignon F, Benso A, Gottero C, Prodam F, Arvat E, Ghè C, Catapano F, Torsello A, Locatelli V, Muccioli G, Boeglin D, Guerlavais V, Fehrentz JA, Martinez J, Ghigo E, Deghenghi R EP1572: a novel peptido-mimetic GH secretagogue with potent and selective GH-releasing activity in man. J. Endocrinol. Invest. 25 8 2002 RC26-8 2572 24002361 10.1038/ja.2013.86 JOURNAL ARTICLE Butler MS, Blaskovich MA, Cooper MA Antibiotics in the clinical pipeline in 2013 J Antibiot (Tokyo) 66 10 2013 571-91 2575 BLA:761092 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761092s000lbl.pdf 2018 2108 27645238 JOURNAL ARTICLE Tsiang M, Jones GS, Goldsmith J, Mulato A, Hansen D, Kan E, Tsai L, Bam RA, Stepan G, Stray KM, Niedziela-Majka A, Yant SR, Yu H, Kukolj G, Cihlar T, Lazerwith SE, White KL, Jin H Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile. Antimicrob. Agents Chemother. 60 12 2016 7086-7097 2208 16135657 JOURNAL ARTICLE Iwanaga T, Kobayashi D, Hirayama M, Maeda T, Tamai I Involvement of uric acid transporter in increased renal clearance of the xanthine oxidase inhibitor oxypurinol induced by a uricosuric agent, benzbromarone. Drug Metab. Dispos. 33 12 2005 1791-5 2308 NDA:021462 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/021462lbl.pdf 2004 2309 BLA:761065 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761065s001lbl.pdf 2018 2310 NDA:209299 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209299lbl.pdf 2018 2311 16946104 10.1124/jpet.106.109058 JOURNAL ARTICLE Braselmann S, Taylor V, Zhao H, Wang S, Sylvain C, Baluom M, Qu K, Herlaar E, Lau A, Young C, Wong BR, Lovell S, Sun T, Park G, Argade A, Jurcevic S, Pine P, Singh R, Grossbard EB, Payan DG, Masuda ES. R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation. https://doi.org/10.1124/jpet.106.109058 J Pharmacol Exp Ther. 319 3 2006 998–1008 2312 NDA:761067 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761067s000lbl.pdf 2018 2313 NDA:761068 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761068s000lbl.pdf 2018 2314 NDA:210493 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210493s000lbl.pdf/drugsatfda_docs/label/2014/125477s007lbl.pdf 2018 2315 BLA:761077 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761077s000lbl.pdf 2018 2316 19183407 10.1111/j.1600-0609.2008.01198.x JOURNAL ARTICLE Fukushima-Shintani M, Suzuki K, Iwatsuki Y, Abe M, Sugasawa K, Hirayama F, Kawasaki T, Nakahata T AKR-501 (YM477) a novel orally-active thrombopoietin receptor agonist. Eur. J. Haematol. 82 4 2009 247-54 2416 NDA:210238 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210238s000lbl.pdf 2018 2417 NDA:210496 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210496lbl.pdf 2018 2418 NDA:210498 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210498lbl.pdf 2018 2419 26559125 10.1124/jpet.115.227793 JOURNAL ARTICLE Shi L, Lehto SG, Zhu DX, Sun H, Zhang J, Smith BP, Immke DC, Wild KD, Xu C Pharmacologic Characterization of AMG 334, a Potent and Selective Human Monoclonal Antibody against the Calcitonin Gene-Related Peptide Receptor. J. Pharmacol. Exp. Ther. 356 1 2016 223-31 2519 NDA:208627 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208627s000lbl.pdf 2018 2521 29670690 10.1021/acsmedchemlett.7b00421 JOURNAL ARTICLE Popovici-Muller J, Lemieux RM, Artin E, Saunders JO, Salituro FG, Travins J, Cianchetta G, Cai Z, Zhou D, Cui D, Chen P, Straley K, Tobin E, Wang F, David MD, Penard-Lacronique V, Quivoron C, Saada V, de Botton S, Gross S, Dang L, Yang H, Utley L, Chen Y, Kim H, Jin S, Gu Z, Yao G, Luo Z, Lv X, Fang C, Yan L, Olaharski A, Silverman L, Biller S, Su SM, Yen K. Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers ACS Med. Chem. Lett. 9 4 2018 300-5 2522 NDA:211192 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211192s000lbl.pdf 2018 2523 19006286 10.1021/jm8006454 JOURNAL ARTICLE Chen C, Wu D, Guo Z, Xie Q, Reinhart GJ, Madan A, Wen J, Chen T, Huang CQ, Chen M, Chen Y, Tucci FC, Rowbottom M, Pontillo J, Zhu YF, Wade W, Saunders J, Bozigian H, Struthers RS Discovery of Sodium R-(+)-4-{2-[5-(2-Fluoro-3-methoxyphenyl)-3-(2-fluoro-6-[trifluoromethyl]benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino}butyrate (Elagolix), a Potent and Orally Available Nonpeptide Antagonist of the Human Gonadotropin-Releasing Hormone Receptor J. Med. Chem. 51 23 2008 7478–85 2524 NDA:210450 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210450s000lbl.pdf 2018 2525 29274361 10.1016/j.exphem.2017.12.005 JOURNAL ARTICLE Yoshida H, Yamada H, Nogami W, Dohi K, Kurino-Yamada T, Sugiyama K, Takahashi K, Gahara Y, Kitaura M, Hasegawa M, Oshima I, Kuwabara K. Development of a new knock-in mouse model and evaluation of pharmacological activities of lusutrombopag, a novel, nonpeptidyl small-molecule agonist of the human thrombopoietin receptor c-Mpl Exp. Hematol. 59 2018 30-39.e2 2526 NDA:211109 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211109lbl.pdf 2018 2527 NDA:210806 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210806s000lbl.pdf 2018 2528 NDA:211155 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211155s000lbl.pdf 2018 2529 24211136 10.1016/j.chembiol.2013.09.017 JOURNAL ARTICLE Winkler DG, Faia KL, DiNitto JP, Ali JA, White KF, Brophy EE, Pink MM, Proctor JL, Lussier J, Martin CM, Hoyt JG, Tillotson B, Murphy EL, Lim AR, Thomas BD, Macdougall JR, Ren P, Liu Y, Li LS, Jessen KA, Fritz CC, Dunbar JL, Porter JR, Rommel C, Palombella VJ, Changelian PS, Kutok JL PI3K-delta and PI3K-gamma inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models. Chem. Biol. 20 11 2013 1364-74 2530 30506139 10.1007/s40265-018-1028-x JOURNAL ARTICLE Shirley M Dacomitinib: First Global Approval. Drugs 78 18 2018 1947-53 2531 NDA:211288 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211288s000lbl.pdf 2018 2532 NDA:209816 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209816_209817lbl.pdf 2018 2533 NDA:211651 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211651s000lbl.pdf 2018 2534 26652717 10.1021/acs.jmedchem.5b01498 JOURNAL ARTICLE Wang B, Chu D, Feng Y, Shen Y, Aoyagi-Scharber M, Post LE Discovery and Characterization of (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) Polymerase-1/2 Inhibitor, as an Anticancer Agent. J. Med. Chem. 59 1 2016 335-57 2535 NDA:210868 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210868s000lbl.pdf 2018 2576 BLA:761102 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761102s000lbl.pdf 2018 2577 NDA:210910 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210910s000lbl.pdf 2018 2536 26144315 10.1016/j.ccell.2015.05.010 JOURNAL ARTICLE Zou HY, Friboulet L, Kodack DP, Engstrom LD, Li Q, West M, Tang RW, Wang H, Tsaparikos K, Wang J, Timofeevski S, Katayama R, Dinh DM, Lam H, Lam JL, Yamazaki S, Hu W, Patel B, Bezwada D, Frias RL, Lifshits E, Mahmood S, Gainor JF, Affolter T, Lappin PB, Gukasyan H, Lee N, Deng S, Jain RK, Johnson TW, Shaw AT, Fantin VR, Smeal T. PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models. Cancer Cell. 28 1 2015 70-81 2537 27401242 10.1158/1078-0432.CCR-16-0917 JOURNAL ARTICLE Facchinetti F, Loriot Y, Kuo MS, Mahjoubi L, Lacroix L, Planchard D, Besse B, Farace F, Auger N, Remon J, Scoazec JY, Andre F, Soria JC, Friboulet L Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers. Clin. Cancer. Res. 22 24 2016 5983-91 2538 25733882 10.1073/pnas.1420785112 JOURNAL ARTICLE Zou HY, Li Q, Engstrom LD, West M, Appleman V, Wong KA, McTigue M, Deng YL, Liu W, Brooun A, Timofeevski S, McDonnell SR, Jiang P, Falk MD, Lappin PB, Affolter T, Nichols T, Hu W, Lam J, Johnson TW, Smeal T, Charest A, Fantin VR PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations. Proc. Natl. Acad. Sci. USA 112 11 2015 3493-98 2539 NDA:210598 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210598s000lbl.pdf 2018 2540 29736245 10.1002/prp2.400 JOURNAL ARTICLE Hegde SS, Pulido-Rios MT, Luttmann MA, Foley JJ, Hunsberger GE, Steinfeld T, Lee T, Ji Y, Mammen MM, Jasper JR Pharmacological properties of revefenacin (TD-4208), a novel, nebulized long-acting, and lung selective muscarinic antagonist, at human recombinant muscarinic receptors and in rat, guinea pig, and human isolated airway tissues. Pharmacol. Res. Perspect. 6 3 2018 e00400 2541 NDA:210656 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210656s000lbl.pdf 2018 2542 24900436 10.1021/ml2002423 JOURNAL ARTICLE Munchhof MJ, Li Q, Shavnya A, Borzillo GV, Boyden TL, Jones CS, LaGreca SD, Martinez-Alsina L, Patel N, Pelletier K, Reiter LA, Robbins MD, Tkalcevic GT Discovery of PF-04449913, a Potent and Orally Bioavailable Inhibitor of Smoothened. ACS Med. Chem. Lett. 3 2 2011 106-11 2543 NDA:210861 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf 2018 2544 21138586 10.1186/1744-8069-6-87 JOURNAL ARTICLE Ghilardi JR, Freeman KT, Jimenez-Andrade JM, Mantyh WG, Bloom AP, Kuskowski MA, Mantyh PW. Administration of a tropomyosin receptor kinase inhibitor attenuates sarcoma-induced nerve sprouting, neuroma formation and bone cancer pain. Mol. Pain 6 1 2010 87 2545 NDA:211349 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211349s000lbl.pdf 2018 2546 27908881 10.1182/blood-2016-10-745133 JOURNAL ARTICLE Lee LY, Hernandez D, Rajkhowa T, Smith SC, Raman JR, Nguyen B, Small D, Levis M Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor Blood 129 2 2017 257-60 2547 29724589 10.1016/j.bmcl.2018.04.055 JOURNAL ARTICLE Miyazaki H, Ikeda Y, Sakurai O, Miyake T, Tsubota R, Okabe J, Kuroda M, Hisada Y, Yanagida T, Yoneda H, Tsukumo Y, Tokunaga S, Kawata T, Ohashi R, Fukuda H, Kojima K, Kannami A, Kifuji T, Sato N, Idei A, Iguchi T, Sakairi T, Moritani Y. Discovery of evocalcet, a next-generation calcium-sensing receptor agonist for the treatment of hyperparathyroidism. Bioorg. Med. Chem. Lett. 28 11 2018 2055-60 2548 30267321 10.1007/s40265-018-0987-2 JOURNAL ARTICLE Syed YY Lanadelumab: First Global Approval. Drugs 78 15 2018 1633-37 2549 NDA:761090 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761090s000lbl.pdf 2018 2550 30411311 10.1007/s40265-018-1006-3 JOURNAL ARTICLE Keam SJ Vibegron: First Global Approval. Drugs 78 17 2018 1835–39 2551 30465134 10.1007/s40265-018-1016-1 JOURNAL ARTICLE Duggan S Omidenepag Isopropyl Ophthalmic Solution 0.002%: First Global Approval. Drugs 78 18 2018 1925-29 2552 30298461 10.1007/s40265-018-0989-0 JOURNAL ARTICLE Duggan S Caplacizumab: First Global Approval. Drugs 78 15 2018 1639-42 2553 BLA:761104 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761104s000lbl.pdf 2018 2554 BLA:761089 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761089s000lbl.pdf 2018 2555 BLA:761063 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761063s000lbl.pdf 2018 2556 BLA:761097 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761097s000lbl.pdf 2018 2557 28265006 10.1158/1535-7163 JOURNAL ARTICLE Burova E, Hermann A, Waite J, Potocky T, Lai V, Hong S, Liu M, Allbritton O, Woodruff A, Wu Q et al Characterization of the Anti-PD-1 Antibody REGN2810 and Its Antitumor Activity in Human PD-1 Knock-In Mice. Mol. Cancer Ther. 16 5 2017 861-870 2558 BLA:761107 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761107s000lbl.pdf 2018 2559 BLA:761108 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761108s000lbl.pdf 2018 2560 29649283 10.1371/journal.pone.0195909 JOURNAL ARTICLE Sheridan D, Yu ZX, Zhang Y, Patel R, Sun F, Lasaro MA, Bouchard K, Andrien B, Marozsan A, Wang Y et al Design and preclinical characterization of ALXN1210: A novel anti-C5 antibody with extended duration of action PLoS ONE 13 4 2018 e0195909 2563 BLA:761116 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761116s000lbl.pdf 2018 2564 NDA:210854 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210854s000lbl.pdf 2018 2565 25531770 10.1371/journal.pone.0114686 JOURNAL ARTICLE Stavros F, Yang A, Leon A, Nuttall M, Rasmussen HS Characterization of structure and function of ZS-9, a K+ selective ion trap PLoS ONE 9 12 2014 e114686 2566 25651699 10.14411/fp.2014.068 JOURNAL ARTICLE Verma M, Pathak M, Shahab M, Singh K, Mitra K, Misra-Bhattacharya S Moxidectin causes adult worm mortality of human lymphatic filarial parasite Brugia malayi in rodent models Folia Parasitol (Praha) 61 6 2014 561-70 2567 23108553 10.1098/rstb.2011.0389 JOURNAL ARTICLE Campos AC, Moreira FA, Gomes FV, Del Bel EA, Guimaraes FS Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders Philos Trans R Soc Lond B Biol Sci 367 1607 2012 3364-78 2568 NDA:210303 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210303Orig1s000lbl.pdf 2018 2569 NDA:210795 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210795s000lbl.pdf 2018 2570 NDA:210922 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210922s000lbl.pdf 2018 2571 NDA:211172 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211172lbl.pdf 2018 2578 NDA:208711 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf 2019 2584 NDA:211371 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211371Orig1s000MultidisciplineR.pdf 2019 2585 NDA:211230 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf 2019 2586 31144287 10.1007/s40265-019-01140-x JOURNAL ARTICLE Al-Salama ZT Siponimod: First global approval Drugs 79 9 2019 1009-15 2587 NDA:212018 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212018s000lbl.pdf 2019 2588 31161538 10.1007/s40265-019-01142-9 JOURNAL ARTICLE Markham A Erdafitinib: First global approval Drugs 79 9 2019 1017-21 2589 NDA:212526 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212526s000lbl.pdf 2019 2590 31256368 10.1007/s40265-019-01161-6 JOURNAL ARTICLE Markham A Alpelisib: First global approval Drugs 79 11 2019 1249-53 2591 NDA:210557 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf 2019 2592 NDA:212306 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212306s000lbl.pdf 2019 2593 BLA:761121 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761121s000lbl.pdf 2019 2594 NDA:212099 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212099Orig1s000lbl.pdf 2019 2595 26137992 10.1038/srep12007 JOURNAL ARTICLE Moilanen AM, Riikonen R, Oksala R, Ravanti L, Aho E, Wohlfahrt G, Nykanen PS, Tormakangas OP, Palvimo JJ, Kallio PJ Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies Sci Rep 5 2015 12007 2599 EMEA/H/C/004538 DRUG LABEL https://www.ema.europa.eu/en/documents/assessment-report/waylivra-epar-public-assessment-report_en.pdf 2019 2600 31301033 10.1007/s40265-019-01168-z JOURNAL ARTICLE Paik J, Duggan S Volanesorsen: First global approval Drugs 79 12 2019 1349-54 2692 BLA:761105 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761105s000lbl.pdf 2019 2693 25905918 10.1080/19420862.2015.1032491 JOURNAL ARTICLE Singh S, Kroe-Barrett RR, Canada KA, Zhu X, Sepulveda E, Wu H, He Y, Raymond EL, Ahlberg J, Frego LE, Amodeo LM, Catron KM, Presky DH, Hanke JH Selective targeting of the IL23 pathway: Generation and characterization of a novel high-affinity humanized anti-IL23A antibody mAbs 7 4 2015 778-91 2694 EMEA/H/C/004128 DRUG LABEL https://www.ema.europa.eu/en/documents/product-information/besremi-epar-product-information_en.pdf 2019 2695 EMEA/H/C/004889 DRUG LABEL https://www.ema.europa.eu/en/documents/product-information/zynquista-epar-product-information_en.pdf 2019 2696 22739142 10.1038/clpt.2012.58 JOURNAL ARTICLE Zambrowicz B, Freiman J, Brown PM, Frazier KS, Turnage A, Bronner J, Ruff D, Shadoan M, Banks P, Mseeh F, Rawlins DB, Goodwin NC, Mabon R, Harrison BA, Wilson A, Sands A, Powell DR LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial Clin Pharmacol Ther 92 2 2012 158-69 2698 BLA:761079 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761079s000lbl.pdf 2019 2699 19754199 10.1021/jm9007533 JOURNAL ARTICLE Chao Q, Sprankle KG, Grotzfeld RM, Lai AG, Carter TA, Velasco AM, Gunawardane RN, Cramer MD, Gardner MF, James J, Zarrinkar PP, Patel HK, Bhagwat SS Identification of N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor J Med Chem 52 23 2009 7808-16 2700 19654408 10.1182/blood-2009-05-222034 JOURNAL ARTICLE Zarrinkar PP, Gunawardane RN, Cramer MD, Gardner MF, Brigham D, Belli B, Karaman MW, Pratz KW, Pallares G, Chao Q, Sprankle KG, Patel HK, Levis M, Armstrong RC, James J, Bhagwat SS AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML) Blood 114 14 2009 2984-92 2701 NCT02215161 CLINICAL TRIAL Phase II single agent study of selinexor (KPT-330) in patients with metastatic castration-resistant prostate cancer (MCRPC) and prior therapy with abiraterone and/or enzalutamide https://clinicaltrials.gov/ProvidedDocs/61/NCT02215161/Prot_SAP_000.pdf 2018 2702 23183107 10.1016/j.ejphar.2012.11.023 JOURNAL ARTICLE Moaddel R, Abdrakhmanova G, Kozak J, Jozwiak K, Toll L, Jimenez L, Rosenberg A, Tran T, Xiao Y, Zarate CA, Wainer IW Sub-anesthetic concentrations of (R,S)-ketamine metabolites inhibit acetylcholine-evoked currents in α7 nicotinic acetylcholine receptors Eur J Pharmacol 698 1-3 2013 228-34 2703 BLA:125586 DRUG LABEL https://www.fda.gov/media/113279/download 2018 2704 12851303 10.1111/j.1749-6632.2003.tb03167.x JOURNAL ARTICLE Molinoff PB, Shadiack AM, Earle D, Diamond LE, Quon CY PT-141: a melanocortin agonist for the treatment of sexual dysfunction Ann N Y Acad Sci 994 1 2003 96-102 2705 BLA:761085 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761085s000lbl.pdf 2019 2706 31383664 10.1128/AAC.00564-19 JOURNAL ARTICLE Tooke CL, Hinchliffe P, Lang PA, Mulholland AJ, Brem J, Schofield CJ, Spencer J Molecular Basis of Class A beta-Lactamase Inhibition by Relebactam Antimicrob Agents Chemother 23 10 2019 e00564-19 2707 26222558 10.1056/NEJMoa1411366 JOURNAL ARTICLE Tap WD, Wainberg ZA, Anthony SP, Ibrahim PN, Zhang C, Healey JH, Chmielowski B, Staddon AP, Cohn AL, Shapiro GI, Keedy VL, Singh AS, Puzanov I, Kwak EL, Wagner AJ, Von Hoff DD, Weiss GJ, Ramanathan RK, Zhang J, Habets G, Zhang Y, Burton EA, Visor G, Sanftner L, Severson P, Nguyen H, Kim MJ, Marimuthu A, Tsang G, Shellooe R, Gee C, West BL, Hirth P, Nolop K, van de Rijn M, Hsu HH, Peterfy C, Lin PS, Tong-Starksen S, Bollag G Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor N Engl J Med 373 5 2015 428-437 690 24170767 10.1158/1535-7163.MCT-12-0993-T JOURNAL ARTICLE Liu N, Rowley BR, Bull CO, Schneider C, Haegebarth A, Schatz CA, Fracasso PR, Wilkie DP, Hentemann M, Wilhelm SM, Scott WJ, Mumberg D, Ziegelbauer K BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110α and p110δ activities in tumor cell lines and xenograft models. Mol. Cancer Ther. 12 11 2013 2319-30 691 NDA:209936 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209936s000lbl.pdf 2017 692 21293470 10.1038/aps.2010.210 JOURNAL ARTICLE Ji XC, Zhao WH, Cao DX, Shi QQ, Wang XL Novel neuroprotectant chiral 3-n-butylphthalide inhibits tandem-pore-domain potassium channel TREK-1. Acta Pharmacol. Sin. 32 2 2011 182-7 665 NDA:208772 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208772lbl.pdf 2017 693 28949138 10.1021/acs.jmedchem.7b01072 JOURNAL ARTICLE Lynagh T, Romero-Rojo JL, Lund C, Pless SA Molecular Basis for Allosteric Inhibition of Acid-Sensing Ion Channel 1a by Ibuprofen. J. Med. Chem. 2017 793 NDA:208716 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208716Orig1s000lbl.pdf 2017 794 24919854 10.1007/s10637-014-0120-7 JOURNAL ARTICLE Gelbert LM, Cai S, Lin X, Sanchez-Martinez C, Del Prado M, Lallena MJ, Torres R, Ajamie RT, Wishart GN, Flack RS, Neubauer BL, Young J, Chan EM, Iversen P, Cronier D, Kreklau E, de Dios A Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine. Invest New Drugs 32 5 2014 825-37 894 21396362 10.1016/j.exer.2011.03.001 JOURNAL ARTICLE Krauss AH, Impagnatiello F, Toris CB, Gale DC, Prasanna G, Borghi V, Chiroli V, Chong WK, Carreiro ST, Ongini E Ocular hypotensive activity of BOL-303259-X, a nitric oxide donating prostaglandin F2α agonist, in preclinical models. Exp. Eye Res. 93 3 2011 250-5 994 NDA:209940 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209939Orig1s000,209940Orig1s000lbl.pdf 2017 995 BLA:761070 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761070s000lbl.pdf 2017 996 26308095 10.1021/acs.jmedchem.5b00726 JOURNAL ARTICLE Lau J, Bloch P, Schäffer L, Pettersson I, Spetzler J, Kofoed J, Madsen K, Knudsen LB, McGuire J, Steensgaard DB, Strauss HM, Gram DX, Knudsen SM, Nielsen FS, Thygesen P, Reedtz-Runge S, Kruse T Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. J. Med. Chem. 58 18 2015 7370-80 1096 NDA:209637 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209637lbl.pdf 2017 1097 27072905 10.1016/j.bmcl.2016.03.104 JOURNAL ARTICLE Sturdivant JM, Royalty SM, Lin CW, Moore LA, Yingling JD, Laethem CL, Sherman B, Heintzelman GR, Kopczynski CC, deLong MA Discovery of the ROCK inhibitor netarsudil for the treatment of open-angle glaucoma. Bioorg. Med. Chem. Lett. 26 10 2016 2475-80 1197 NDA:208254 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208254lbl.pdf 2017 1198 26641137 10.1056/NEJMoa1509981 JOURNAL ARTICLE Byrd JC, Harrington B, O'Brien S, Jones JA, Schuh A, Devereux S, Chaves J, Wierda WG, Awan FT, Brown JR, Hillmen P, Stephens DM, Ghia P, Barrientos JC, Pagel JM, Woyach J, Johnson D, Huang J, Wang X, Kaptein A, Lannutti BJ, Covey T, Fardis M, McGreivy J, Hamdy A, Rothbaum W, Izumi R, Diacovo TG, Johnson AJ, Furman RR Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia. N. Engl. J. Med. 374 4 2016 323-32 1298 NDA:210259 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/210259s000lbl.pdf 2017 1299 EMEA/H/C/004131 DRUG LABEL http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004131/WC500239033.pdf 2017 1300 16982756 JOURNAL ARTICLE Nakamura K, Taguchi E, Miura T, Yamamoto A, Takahashi K, Bichat F, Guilbaud N, Hasegawa K, Kubo K, Fujiwara Y, Suzuki R, Kubo K, Shibuya M, Isae T KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties. Cancer Res. 66 18 2006 9134-42 1400 14623894 JOURNAL ARTICLE Pham V, Wade JD, Purdue BW, Sexton PM Spatial proximity between a photolabile residue in position 19 of salmon calcitonin and the amino terminus of the human calcitonin receptor. J. Biol. Chem. 279 8 2004 6720-9 1500 10385705 JOURNAL ARTICLE Christopoulos G, Perry KJ, Morfis M, Tilakaratne N, Gao Y, Fraser NJ, Main MJ, Foord SM, Sexton PM Multiple amylin receptors arise from receptor activity-modifying protein interaction with the calcitonin receptor gene product. Mol. Pharmacol. 56 1 1999 235-42 1600 15692146 JOURNAL ARTICLE Hay DL, Christopoulos G, Christopoulos A, Poyner DR, Sexton PM Pharmacological discrimination of calcitonin receptor: receptor activity-modifying protein complexes. Mol. Pharmacol. 67 5 2005 1655-65 1700 21449606 10.1021/jm200049r JOURNAL ARTICLE Mascitti V, Maurer TS, Robinson RP, Bian J, Boustany-Kari CM, Brandt T, Collman BM, Kalgutkar AS, Klenotic MK, Leininger MT, Lowe A, Maguire RJ, Masterson VM, Miao Z, Mukaiyama E, Patel JD, Pettersen JC, Préville C, Samas B, She L, Sobol Z, Steppan CM, Stevens BD, Thuma BA, Tugnait M, Zeng D, Zhu T Discovery of a clinical candidate from the structurally unique dioxa-bicyclo[3.2.1]octane class of sodium-dependent glucose cotransporter 2 inhibitors. J. Med. Chem. 54 8 2011 2952-60 1800 NDA:209803 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209803s000lbl.pdf 2017 1801 10193788 JOURNAL ARTICLE Vanderheyden PM, Fierens FL, De Backer JP, Fraeyman N, Vauquelin G Distinction between surmountable and insurmountable selective AT1 receptor antagonists by use of CHO-K1 cells expressing human angiotensin II AT1 receptors. Br. J. Pharmacol. 126 4 1999 1057-65 1901 NDA:209360 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209360s000lbl.pdf 2017 1902 NDA:210251 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209360s000lbl.pdf 2018 1903 22266222 10.1158/0008-5472.CAN-11-3948 JOURNAL ARTICLE Clegg NJ, Wongvipat J, Joseph JD, Tran C, Ouk S, Dilhas A, Chen Y, Grillot K, Bischoff ED, Cai L, Aparicio A, Dorow S, Arora V, Shao G, Qian J, Zhao H, Yang G, Cao C, Sensintaffar J, Wasielewska T, Herbert MR, Bonnefous C, Darimont B, Scher HI, Smith-Jones P, Klang M, Smith ND, De Stanchina E, Wu N, Ouerfelli O, Rix PJ, Heyman RA, Jung ME, Sawyers CL, Hager JH ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res. 72 6 2012 1494-503 2003 NDA:210951 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210951s000lbl.pdf 2018 659 22711801 10.1073/pnas.1204524109 JOURNAL ARTICLE Gregori-Puigjané E, Setola V, Hert J, Crews BA, Irwin JJ, Lounkine E, Marnett L, Roth BL, Shoichet BK Identifying mechanism-of-action targets for drugs and probes. Proc. Natl. Acad. Sci. U.S.A. 109 28 2012 11178-83 660 9628722 JOURNAL ARTICLE Miles RW, Tyler PC, Furneaux RH, Bagdassarian CK, Schramm VL One-third-the-sites transition-state inhibitors for purine nucleoside phosphorylase. Biochemistry 37 24 1998 8615-21 661 17897085 JOURNAL ARTICLE Korycka A, Błoński JZ, Robak T Forodesine (BCX-1777, Immucillin H)--a new purine nucleoside analogue: mechanism of action and potential clinical application. Mini Rev Med Chem 7 9 2007 976-83 662 NDA:207997 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207997Orig1Orig2s000lbl.pdf 2017 663 NDA:208743 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208743lbl.pdf 2017 664 26562265 10.1210/en.2015-1726 JOURNAL ARTICLE Hattersley G, Dean T, Corbin BA, Bahar H, Gardella TJ Binding Selectivity of Abaloparatide for PTH-Type-1-Receptor Conformations and Effects on Downstream Signaling. Endocrinology 157 1 2016 141-9 666 27780853 10.1158/1078-0432.CCR-16-0569 JOURNAL ARTICLE Zhang S, Anjum R, Squillace R, Nadworny S, Zhou T, Keats J, Ning Y, Wardwell SD, Miller D, Song Y, Eichinger L, Moran L, Huang WS, Liu S, Zou D, Wang Y, Mohemmad Q, Jang HG, Ye E, Narasimhan N, Wang F, Miret J, Zhu X, Clackson T, Dalgarno D, Shakespeare WC, Rivera VM The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models. Clin. Cancer Res. 22 22 2016 5527-5538 667 BLA:761069 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761069s000lbl.pdf 2017 668 BLA:761052 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761052lbl.pdf 2017 669 ANDA:064047 DRUG LABEL https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b7aa0bae-255b-4792-a963-6606370a175f 2009 670 NDA:050740 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050740s021lbl.pdf 2012 671 BLA:761037 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761037s000lbl.pdf 2017 672 14761182 JOURNAL ARTICLE Shin SS, Byun Y, Lim KM, Choi JK, Lee KW, Moh JH, Kim JK, Jeong YS, Kim JY, Choi YH, Koh HJ, Park YH, Oh YI, Noh MS, Chung S In vitro structure-activity relationship and in vivo studies for a novel class of cyclooxygenase-2 inhibitors: 5-aryl-2,2-dialkyl-4-phenyl-3(2H)furanone derivatives. J. Med. Chem. 47 4 2004 792-804 673 21570283 10.1016/j.bmcl.2011.04.029 JOURNAL ARTICLE Kim HJ, Kwak WY, Min JP, Lee JY, Yoon TH, Kim HD, Shin CY, Kim MK, Choi SH, Kim HS, Yang EK, Cheong YH, Chae YN, Park KJ, Jang JM, Choi SJ, Son MH, Kim SH, Yoo M, Lee BJ Discovery of DA-1229: a potent, long acting dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. Bioorg. Med. Chem. Lett. 21 12 2011 3809-12 674 21093089 10.1016/j.diabres.2010.10.012 JOURNAL ARTICLE Cho JM, Jang HW, Cheon H, Jeong YT, Kim DH, Lim YM, Choi SH, Yang EK, Shin CY, Son MH, Kim SH, Kim HJ, Lee MS A novel dipeptidyl peptidase IV inhibitor DA-1229 ameliorates streptozotocin-induced diabetes by increasing β-cell replication and neogenesis. Diabetes Res. Clin. Pract. 91 1 2011 72-9 675 22278334 10.1038/clpt.2012.3 JOURNAL ARTICLE Skarke C, Alamuddin N, Lawson JA, Cen L, Propert KJ, Fitzgerald GA Comparative impact on prostanoid biosynthesis of celecoxib and the novel nonsteroidal anti-inflammatory drug CG100649. Clin. Pharmacol. Ther. 91 6 2012 986-93 676 19297154 10.1016/j.bmcl.2009.02.111 JOURNAL ARTICLE Zhang P, Huang W, Wang L, Bao L, Jia ZJ, Bauer SM, Goldman EA, Probst GD, Song Y, Su T, Fan J, Wu Y, Li W, Woolfrey J, Sinha U, Wong PW, Edwards ST, Arfsten AE, Clizbe LA, Kanter J, Pandey A, Park G, Hutchaleelaha A, Lambing JL, Hollenbach SJ, Scarborough RM, Zhu BY Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitor. Bioorg. Med. Chem. Lett. 19 8 2009 2179-85 677 NDA:208383 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208383s000lbl.pdf 2017 678 1446593 JOURNAL ARTICLE LaPolt PS, Nishimori K, Fares FA, Perlas E, Boime I, Hsueh AJ Enhanced stimulation of follicle maturation and ovulatory potential by long acting follicle-stimulating hormone agonists with extended carboxyl-terminal peptides. Endocrinology 131 6 1992 2514-20 679 BLA:761061 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761061s000lbl.pdf 2017 680 EMEA/H/C/004119 DRUG LABEL http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004119/WC500231261.pdf 2017 681 17553678 10.1016/j.bmcl.2007.05.066 JOURNAL ARTICLE Yamazaki Y, Abe K, Toma T, Nishikawa M, Ozawa H, Okuda A, Araki T, Oda S, Inoue K, Shibuya K, Staels B, Fruchart JC Design and synthesis of highly potent and selective human peroxisome proliferator-activated receptor alpha agonists. Bioorg. Med. Chem. Lett. 17 16 2007 4689-93 682 JOURNAL ARTICLE Bai AP, Guo ZR, Hu WH, Shen F, Cheng GF. Design, synthesis and in vitro evaluation of a new class of novel cyclooxygenase-2 inhibitors: 3,4-diaryl-3-pyrrolin-2-ones. Chin Chem Lett 12 9 2001 775–8 683 NDA:209195 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209195s000lbl.pdf 2017 684 28193778 10.1158/2159-8290.CD-16-1034 JOURNAL ARTICLE Yen K, Travins J, Wang F, David MD, Artin E, Straley K, Padyana A, Gross S, DeLaBarre B, Tobin E, Chen Y, Nagaraja R, Choe S, Jin L, Konteatis Z, Cianchetta G, Saunders JO, Salituro FG, Quivoron C, Opolon P, Bawa O, Saada V, Paci A, Broutin S, Bernard OA, de Botton S, Marteyn BS, Pilichowska M, Xu Y, Fang C, Jiang F, Wei W, Jin S, Silverman L, Liu W, Yang H, Dang L, Dorsch M, Penard-Lacronique V, Biller SA, Su SM AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations. Cancer Discov 7 5 2017 478-493 685 NDA:209606 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209606s000lbl.pdf 2017 686 15715478 JOURNAL ARTICLE Tsou HR, Overbeek-Klumpers EG, Hallett WA, Reich MF, Floyd MB, Johnson BD, Michalak RS, Nilakantan R, Discafani C, Golas J, Rabindran SK, Shen R, Shi X, Wang YF, Upeslacis J, Wissner A Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity. J. Med. Chem. 48 4 2005 1107-31 687 NDA:208051 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208051s000lbl.pdf 2017 688 15210067 JOURNAL ARTICLE Chen XH, Bai JY, Shen F, Bai AP, Guo ZR, Cheng GF Imrecoxib: a novel and selective cyclooxygenase 2 inhibitor with anti-inflammatory effect. Acta Pharmacol. Sin. 25 7 2004 927-31 689 EMEA/H/C/004209 DRUG LABEL http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004209/WC500232105.pdf 2017 628 NDA:209115 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/209115s000lbl.pdf 2016 629 10.1021/acs.jmedchem.6b00990 JOURNAL ARTICLE Thorsell, Ann-Gerd and Ekblad, Torun and Karlberg, Tobias and Löw, Mirjam and Pinto, Ana Filipa and Tresaugues, Lionel and Moche, Martin and Cohen, Michael S. and Schüler, Herwig Structural basis for potency and promiscuity in poly(ADP-ribose) polymerase (PARP) and tankyrase inhibitors J. Med. Chem. 2016 630 20188549 10.1016/j.bmcl.2010.02.010 JOURNAL ARTICLE Zhang YK, Plattner JJ, Akama T, Baker SJ, Hernandez VS, Sanders V, Freund Y, Kimura R, Bu W, Hold KM, Lu XS Design and synthesis of boron-containing PDE4 inhibitors using soft-drug strategy for potential dermatologic anti-inflammatory application. Bioorg. Med. Chem. Lett. 20 7 2010 2270-4 631 NDA:207695 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207695s000lbl.pdf 2016 619 BLA:125293 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125293s085lbl.pdf 2016 632 20363976 10.4049/jimmunol.0902819 JOURNAL ARTICLE Fridman JS, Scherle PA, Collins R, Burn TC, Li Y, Li J, Covington MB, Thomas B, Collier P, Favata MF, Wen X, Shi J, McGee R, Haley PJ, Shepard S, Rodgers JD, Yeleswaram S, Hollis G, Newton RC, Metcalf B, Friedman SM, Vaddi K Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. J. Immunol. 184 9 2010 5298-307 633 22959248 10.1016/j.bmcl.2012.06.067 JOURNAL ARTICLE Hu S, Xie G, Zhang DX, Davis C, Long W, Hu Y, Wang F, Kang X, Tan F, Ding L, Wang Y Synthesis and biological evaluation of crown ether fused quinazoline analogues as potent EGFR inhibitors. Bioorg. Med. Chem. Lett. 22 19 2012 6301-5 634 22088449 JOURNAL ARTICLE Wang HP, Zhang L, Wang YX, Tan FL, Xia Y, Ren GJ, Hu P, Jiang J, Wang MZ, Xiao Y Phase I trial of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in Chinese patients with non-small cell lung cancer. Chin. Med. J. 124 13 2011 1933 635 27357069 10.1007/s40265-016-0606-z JOURNAL ARTICLE Kim ES Olmutinib: First Global Approval. Drugs 76 11 2016 1153-7 636 NDA:208745 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208745lbl.pdf 2017 637 26558155 10.4292/wjgpt.v6.i4.213 JOURNAL ARTICLE Shailubhai K, Palejwala V, Arjunan KP, Saykhedkar S, Nefsky B, Foss JA, Comiskey S, Jacob GS, Plevy SE Plecanatide and dolcanatide, novel guanylate cyclase-C agonists, ameliorate gastrointestinal inflammation in experimental models of murine colitis. World J Gastrointest Pharmacol Ther 6 4 2015 213-22 638 24900196 10.1021/ml1000257 JOURNAL ARTICLE Xu L, Liu H, Murray BP, Callebaut C, Lee MS, Hong A, Strickley RG, Tsai LK, Stray KM, Wang Y, Rhodes GR, Desai MC Cobicistat (GS-9350): A Potent and Selective Inhibitor of Human CYP3A as a Novel Pharmacoenhancer. ACS Med Chem Lett 1 5 2010 209-13 639 NDA:203094 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/203094s005lbl.pdf 2016 640 25676420 10.1038/leu.2015.42 JOURNAL ARTICLE Zabriskie MS, Vellore NA, Gantz KC, Deininger MW, O'Hare T Radotinib is an effective inhibitor of native and kinase domain-mutant BCR-ABL1. Leukemia 29 9 2015 1939-42 641 21443688 10.1111/j.1349-7006.2011.01939.x JOURNAL ARTICLE Tian S, Quan H, Xie C, Guo H, Lü F, Xu Y, Li J, Lou L YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo. Cancer Sci. 102 7 2011 1374-80 642 28041831 10.1016/j.bmcl.2016.12.053 JOURNAL ARTICLE Goldberg DR, De Lombaert S, Aiello R, Bourassa P, Barucci N, Zhang Q, Paralkar V, Stein AJ, Holt M, Valentine J, Zavadoski W Optimization of spirocyclic proline tryptophan hydroxylase-1 inhibitors. Bioorg. Med. Chem. Lett. 27 3 2017 413-419 643 BLA:125359 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125359s088lbl.pdf 2016 644 NDA:208794 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208794s000lbl.pdf 2017 645 11314603 JOURNAL ARTICLE Nagatomo T, Hosohata Y, Ohnuki T, Nakamura T, Hattori K, Suzuki J, Ishiguro M Bopindolol: pharmacological basis and clinical implications. Cardiovasc Drug Rev 19 1 2001 9-24 646 12152654 JOURNAL ARTICLE Gils A, Stassen JM, Nar H, Kley JT, Wienen W, Ries UJ, Declerck PJ Characterization and comparative evaluation of a novel PAI-1 inhibitor. Thromb. Haemost. 88 1 2002 137-43 647 PL 0458/0027 DRUG LABEL http://www.medicines.org.uk/emc/medicine/1073 2017 648 EMEA/H/C/004085 DRUG LABEL http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004085/WC500223723.pdf 2017 649 27144355 10.1038/nature17998 JOURNAL ARTICLE Zanos P, Moaddel R, Morris PJ, Georgiou P, Fischell J, Elmer GI, Alkondon M, Yuan P, Pribut HJ, Singh NS, Dossou KS, Fang Y, Huang XP, Mayo CL, Wainer IW, Albuquerque EX, Thompson SM, Thomas CJ, Zarate CA, Gould TD NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature 533 7604 2016 481-6 650 NDA:209092 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209092s000lbl.pdf 2017 651 25941111 10.1158/1078-0432.CCR-14-0816 JOURNAL ARTICLE VanArsdale T, Boshoff C, Arndt KT, Abraham RT Molecular Pathways: Targeting the Cyclin D-CDK4/6 Axis for Cancer Treatment. Clin. Cancer Res. 21 13 2015 2905-10 652 NDA:208854 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208854s000lbl.pdf 2017 653 NDA:208447 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208447lbl.pdf 2017 654 BLA:761049 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761049s000lbl.pdf 2017 655 BLA:761053 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761053lbl.pdf 2017 656 BLA:761055 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761055lbl.pdf 2017 657 NDA:208082 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208082s000lbl.pdf 2017 658 NDA:209241 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209241lbl.pdf 2017 626 22455412 10.1056/NEJMoa1109017 JOURNAL ARTICLE Papp KA, Leonardi C, Menter A, Ortonne JP, Krueger JG, Kricorian G, Aras G, Li J, Russell CB, Thompson EH, Baumgartner S Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N. Engl. J. Med. 366 13 2012 1181-9 627 EMEA/H/C/003995 DRUG LABEL http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003995/WC500217100.pdf 2016 625 BLA:761046 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/761046s000lbl.pdf 2016 623 9537821 JOURNAL ARTICLE Tatsumi M, Groshan K, Blakely RD, Richelson E Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur. J. Pharmacol. 340 2-3 1997 249-58 624 BLA:761038 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/761038lbl.pdf 2016 615 24900456 10.1021/ml2002482 JOURNAL ARTICLE Zhong M, Gadek TR, Bui M, Shen W, Burnier J, Barr KJ, Hanan EJ, Oslob JD, Yu CH, Zhu J, Arkin MR, Evanchik MJ, Flanagan WM, Hoch U, Hyde J, Prabhu S, Silverman JA, Wright J Discovery and Development of Potent LFA-1/ICAM-1 Antagonist SAR 1118 as an Ophthalmic Solution for Treating Dry Eye. ACS Med Chem Lett 3 3 2012 203-6 616 NDA:208073 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208073s000lbl.pdf 2016 617 NDA:208524 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208524s000lbl.pdf 2016 618 23301156 10.1038/srep01035 JOURNAL ARTICLE Realini N, Solorzano C, Pagliuca C, Pizzirani D, Armirotti A, Luciani R, Costi MP, Bandiera T, Piomelli D Discovery of highly potent acid ceramidase inhibitors with in vitro tumor chemosensitizing activity. Sci Rep 3 2013 1035 620 24113750 10.1124/mol.113.089482 JOURNAL ARTICLE MacKenzie AE, Caltabiano G, Kent TC, Jenkins L, McCallum JE, Hudson BD, Nicklin SA, Fawcett L, Markwick R, Charlton SJ, Milligan G The antiallergic mast cell stabilizers lodoxamide and bufrolin as the first high and equipotent agonists of human and rat GPR35. Mol. Pharmacol. 85 1 2014 91-104 622 EMEA/H/C/000253 DRUG LABEL http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000253/WC500040495.pdf 2016 586 BLA:125499 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125499s009lbl.pdf 2015 587 BLA:103628 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/103628s5258lbl.pdf 2015 588 BLA:103471 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/103471s5188lbl.pdf 2015 589 BLA:103172 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/103172s5203lbl.pdf 2015 590 16469866 JOURNAL ARTICLE Vanover KE, Weiner DM, Makhay M, Veinbergs I, Gardell LR, Lameh J, Del Tredici AL, Piu F, Schiffer HH, Ott TR, Burstein ES, Uldam AK, Thygesen MB, Schlienger N, Andersson CM, Son TY, Harvey SC, Powell SB, Geyer MA, Tolf BR, Brann MR, Davis RE Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist. J. Pharmacol. Exp. Ther. 317 2 2006 910-8 591 NDA:207318 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207318lbl.pdf 2016 592 24847974 10.1021/jm500475k JOURNAL ARTICLE Lanier M, Ambrus G, Cole DC, Davenport R, Ellery J, Fosbeary R, Jennings AJ, Kadotani A, Kamada Y, Kamran R, Matsumoto S, Mizukami A, Okubo S, Okada K, Saikatendu K, Walsh L, Wu H, Hixon MS A fragment-based approach to identifying S-adenosyl-l-methionine -competitive inhibitors of catechol O-methyl transferase (COMT). J. Med. Chem. 57 12 2014 5459-63 593 BLA:761034 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/761034s000lbl.pdf 2016 594 9713295 JOURNAL ARTICLE Denis L, Debruyne F, De Porre P, Bruynseels J Early clinical experience with liarozole (Liazal) in patients with progressive prostate cancer. Eur. J. Cancer 34 4 1998 469-75 595 21762037 10.1517/14728222.2011.600692 JOURNAL ARTICLE Antoniu SA Terguride for pulmonary arterial hypertension. Expert Opin. Ther. Targets 15 11 2011 1333-5 596 15627429 JOURNAL ARTICLE Thierry C, Boeynaems JM, Paolo M Actions of tilidine and nortilidine on cloned opioid receptors. Eur. J. Pharmacol. 506 3 2005 205-8 597 11523024 JOURNAL ARTICLE Karp JE Farnesyl protein transferase inhibitors as targeted therapies for hematologic malignancies. Semin. Hematol. 38 3 Suppl 7 2001 16-23 598 EMEA/H/C/004059 DRUG LABEL http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004059/WC500208434.pdf 2016 599 12166927 JOURNAL ARTICLE Pellicciari R, Fiorucci S, Camaioni E, Clerici C, Costantino G, Maloney PR, Morelli A, Parks DJ, Willson TM 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J. Med. Chem. 45 17 2002 3569-72 600 NDA:207999 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207999s000lbl.pdf 2016 601 8736619 JOURNAL ARTICLE Patel SS, Wilde MI Ebrotidine. Drugs 51 6 1996 974-80; discussion 981 602 7693433 JOURNAL ARTICLE Goa KL, Brogden RN Propiram. A review of its pharmacodynamic and pharmacokinetic properties, and clinical use as an analgesic. Drugs 46 3 1993 428-45 603 6141283 JOURNAL ARTICLE Spiegel K, Pasternak GW Meptazinol: a novel Mu-1 selective opioid analgesic. J. Pharmacol. Exp. Ther. 228 2 1984 414-9 604 BLA:103951 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/103951s5363lbl.pdf 2015 605 BLA:103964 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/103964s5264lbl.pdf 2015 606 EMEA/H/C/000116 DRUG LABEL http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000116/WC500024979.pdf 2015 607 BLA:103949 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/103949s5299lbl.pdf 2015 608 BLA:125164 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125164s071s072s073lbl.pdf 2016 609 10776839 JOURNAL ARTICLE Dunn CJ, Goa KL Lenograstim: an update of its pharmacological properties and use in chemotherapy-induced neutropenia and related clinical settings. Drugs 59 3 2000 681-717 610 EMEA/H/C/000872 DRUG LABEL http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000872/WC500054377.pdf 2015 611 NDA:022081 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022081s033lbl.pdf 2015 612 9875499 JOURNAL ARTICLE Lee JH, Lee JM, Kim JK, Ahn SK, Lee SJ, Kim MY, Jew SS, Park JG, Hong CI Antitumor activity of 7-[2-(N-isopropylamino)ethyl]-(20S)-camptothecin, CKD602, as a potent DNA topoisomerase I inhibitor. Arch. Pharm. Res. 21 5 1998 581-90 613 NDA:208341 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208341s000lbl.pdf 2016 614 2853885 JOURNAL ARTICLE Scherman D, Hamon M, Gozlan H, Henry JP, Lesage A, Masson M, Rumigny JF Molecular pharmacology of niaprazine. Prog. Neuropsychopharmacol. Biol. Psychiatry 12 6 1988 989-1001 583 23291630 10.1038/nm.3048 JOURNAL ARTICLE Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, Dayton BD, Ding H, Enschede SH, Fairbrother WJ, Huang DC, Hymowitz SG, Jin S, Khaw SL, Kovar PJ, Lam LT, Lee J, Maecker HL, Marsh KC, Mason KD, Mitten MJ, Nimmer PM, Oleksijew A, Park CH, Park CM, Phillips DC, Roberts AW, Sampath D, Seymour JF, Smith ML, Sullivan GM, Tahir SK, Tse C, Wendt MD, Xiao Y, Xue JC, Zhang H, Humerickhouse RA, Rosenberg SH, Elmore SW ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat. Med. 19 2 2013 202-8 584 NDA:208573 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208573s000lbl.pdf 2016 585 BLA:103532 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/103532s5175lbl.pdf 2014 530 20040696 10.1345/aph.1M347 JOURNAL ARTICLE Gish EC, Miller JL, Honey BL, Johnson PN Lofexidine, an {alpha}2-receptor agonist for opioid detoxification. Ann Pharmacother 44 2 2010 343-51 531 BLA:103411 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/103411s5180lbl.pdf 2014 532 NDA:208261 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208261Orig1s000lbl.pdf 2016 574 EU/3/11/869 DRUG LABEL http://www.ema.europa.eu/docs/en_GB/document_library/Orphan_designation/2011/05/WC500106736.pdf 2013 533 12487507 JOURNAL ARTICLE Ishide T Denopamine, a selective beta1-receptor agonist and a new coronary vasodilator. Curr Med Res Opin 18 7 2002 407-13 534 7726994 JOURNAL ARTICLE Wouters W, Snoeck E, De Coster R Vorozole, a specific non-steroidal aromatase inhibitor. Breast Cancer Res. Treat. 30 1 1994 89-94 535 NDA:021396 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/21396_prempro_lbl.pdf 2003 536 2154989 JOURNAL ARTICLE Morii M, Takata H, Fujisaki H, Takeguchi N The potency of substituted benzimidazoles such as E3810, omeprazole, Ro 18-5364 to inhibit gastric H+, K(+)-ATPase is correlatedwith the rate of acid-activation of the inhibitor. Biochem. Pharmacol. 39 4 1990 661-7 537 11304936 JOURNAL ARTICLE Kwon D, Chae JB, Park CW, Kim YS, Lee SM, Kim EJ, Huh IH, Kim DY, Cho KD Effects of IY-81149, a newly developed proton pump inhibitor, on gastric acid secretion in vitro and in vivo. Arzneimittelforschung 51 3 2001 204-13 538 NDA:021825 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021825s003lbl.pdf 2015 539 9298526 JOURNAL ARTICLE Uneyama H, Takahara A, Dohmoto H, Yoshimoto R, Inoue K, Akaike N Blockade of N-type Ca2+ current by cilnidipine (FRC-8653) in acutely dissociated rat sympathetic neurones. Br. J. Pharmacol. 122 1 1997 37-42 540 NDA:019481 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/019481s013lbl.pdf 2015 541 4859983 JOURNAL ARTICLE Casdorph HR Hypercholesteremia. Treatment with cholestyramine, a bile acid sequestering resin. Calif Med 106 4 1967 293-5 542 NDA:016267 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/016267s050lbl.pdf 2011 543 2547493 JOURNAL ARTICLE Klöckner U, Isenberg G The dihydropyridine niguldipine modulates calcium and potassium currents in vascular smooth muscle cells. Br. J. Pharmacol. 97 3 1989 957-67 544 8287905 JOURNAL ARTICLE Tohse N, Takeda Y, Kanno M Voltage-dependent modulation of L-type Ca2+ current by manidipine in guinea-pig heart cells. Eur. J. Pharmacol. 249 2 1993 231-3 545 7898101 JOURNAL ARTICLE Rosenthal J Nilvadipine: profile of a new calcium antagonist. An overview. J. Cardiovasc. Pharmacol. 24 Suppl 2 1994 S92-107 546 EMEA/H/C/000802 DRUG LABEL http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000802/WC500026565.pdf 2016 547 22455413 10.1056/NEJMoa1109997 JOURNAL ARTICLE Leonardi C, Matheson R, Zachariae C, Cameron G, Li L, Edson-Heredia E, Braun D, Banerjee S Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N. Engl. J. Med. 366 13 2012 1190-9 548 10533013 JOURNAL ARTICLE Wright RO, Lewander WJ, Woolf AD Methemoglobinemia: etiology, pharmacology, and clinical management. Ann Emerg Med 34 5 1999 646-56 549 12749884 JOURNAL ARTICLE Faul MM, Gillig JR, Jirousek MR, Ballas LM, Schotten T, Kahl A, Mohr M Acyclic N-(azacycloalkyl)bisindolylmaleimides: isozyme selective inhibitors of PKCbeta. Bioorg. Med. Chem. Lett. 13 11 2003 1857-9 550 16891464 JOURNAL ARTICLE Rizvi MA, Ghias K, Davies KM, Ma C, Weinberg F, Munshi HG, Krett NL, Rosen ST Enzastaurin (LY317615), a protein kinase Cbeta inhibitor, inhibits the AKT pathway and induces apoptosis in multiple myeloma cell lines. Mol. Cancer Ther. 5 7 2006 1783-9 551 9126675 JOURNAL ARTICLE Scholz H Pharmacological aspects of calcium channel blockers. Cardiovasc Drugs Ther 10 Suppl 3 1997 869-72 552 17213004 JOURNAL ARTICLE Park JY, Kim KA, Park PW, Lee OJ, Ryu JH, Lee GH, Ha MC, Kim JS, Kang SW, Lee KR Pharmacokinetic and pharmacodynamic characteristics of a new S-amlodipine formulation in healthy Korean male subjects: a randomized, open-label, two-period, comparative, crossover study. Clin Ther 28 11 2006 1837-47 553 8821512 JOURNAL ARTICLE Guarneri L, Angelico P, Ibba M, Poggesi E, Taddei C, Leonardi A, Testa R Pharmacological in vitro studies of the new 1,4-dihydropyridine calcium antagonist lercanidipine. Arzneimittelforschung 46 1 1996 15-24 554 ANDA:077394 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/077394lbl.pdf 2005 555 NDA:021160 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2001/21160lbl.pdf 2001 556 NDA:022127 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022127s011lbl.pdf 2014 557 NDA:019071 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/019071s012lbl.pdf 2009 559 18655903 10.1016/S0079-6123(08)00437-8 JOURNAL ARTICLE Manning M, Stoev S, Chini B, Durroux T, Mouillac B, Guillon G Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents. Prog. Brain Res. 170 2008 473-512 560 NDA:203756 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203756lbl.pdf 2012 561 NDA:020452 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020452s005lbl.pdf 2010 562 NDA:050682 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050682s029s030lbl.pdf 2012 563 NDA:020221 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020221s024lbl.pdf 2008 564 NDA:020954 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020954s014lbl.pdf 2015 565 NDA:020038 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020038s033lbl.pdf 2010 566 3025043 JOURNAL ARTICLE Yoshida T, Nishioka H, Yoshioka K, Nakano K, Kondo M, Terashima H Effect of aldose reductase inhibitor ONO 2235 on reduced sympathetic nervous system activity and peripheral nerve disorders in STZ-induced diabetic rats. Diabetes 36 1 1987 6-13 567 1278093 JOURNAL ARTICLE Taurog A The mechanism of action of the thioureylene antithyroid drugs. Endocrinology 98 4 1976 1031-46 568 6356910 JOURNAL ARTICLE Kerwar SS Pharmacologic properties of fenbufen. Am. J. Med. 75 4B 1983 62-9 569 23755755 JOURNAL ARTICLE Maenthaisong R, Tacconelli S, Sritara P, Del Boccio P, Di Francesco L, Sacchetta P, Archararit N, Aryurachai K, Patrignani P, Suthisisang C Clinical pharmacology of cyclooxygenase inhibition and pharmacodynamic interaction with aspirin by floctafenine in Thai healthy subjects. Int J Immunopathol Pharmacol 26 2 403-17 570 BLA:103767 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/103767s5119lbl.pdf 2011 571 BLA:125036 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125036s0144lbl.pdf 2012 572 BLA:125118 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125118s179lbl.pdf 2014 573 NDA:207155 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207155s000lbl.pdf 2016 575 BLA:125288 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125288s062lbl.pdf 2014 576 BLA:125521 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125521s000lbl.pdf 2016 577 BLA:125509 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125509lbl.pdf 2016 578 BLA:761033 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/761033lbl.pdf 2016 579 BLA:125249 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/125249lbl.pdf 2008 580 NDA:021846 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021846s101lbl.pdf 2008 581 NDA:205109 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205109s001lbl.pdf 2014 582 NDA:020057 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/020057s034lbl.pdf 2006 477 BLA:103909 DRUG LABEL http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/UCM200875.pdf 2000 478 NDA:208462 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/208462lbl.pdf 2015 479 20160034 10.1158/0008-5472.CAN-09-2766 JOURNAL ARTICLE Kupperman E, Lee EC, Cao Y, Bannerman B, Fitzgerald M, Berger A, Yu J, Yang Y, Hales P, Bruzzese F, Liu J, Blank J, Garcia K, Tsu C, Dick L, Fleming P, Yu L, Manfredi M, Rolfe M, Bolen J Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Res. 70 5 2010 1970-80 480 18500360 10.1038/bjp.2008.198 JOURNAL ARTICLE Matagne A, Margineanu DG, Kenda B, Michel P, Klitgaard H Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A. Br. J. Pharmacol. 154 8 2008 1662-71 481 BLA:761036 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/761036Orig1s000lbledt.pdf 2015 482 BLA:101063 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/101063s5169lbl.pdf 2013 483 BLA:125547 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125547s000lbl.pdf 2015 484 2905151 JOURNAL ARTICLE Vincent J, Sumner DJ, Reid JL Ebastine: the effect of a new antihistamine on psychomotor performance and autonomic responses in healthy subjects. Br J Clin Pharmacol 26 5 1988 503-8 485 1982751 JOURNAL ARTICLE Porszász J, Varga F, Porszász KG, Szolscányi J, Barthó L, Petöcz L, Kápolnai L Pharmacology of the new H1-receptor antagonist setastine hydrochloride. Arzneimittelforschung 40 12 1990 1340-5 486 1354949 JOURNAL ARTICLE Rosenzweig P, Thebault JJ, Caplain H, Dubruc C, Bianchetti G, Fuseau E, Morselli PL Pharmacodynamics and pharmacokinetics of mizolastine (SL 85.0324), a new nonsedative H1 antihistamine. Ann Allergy 69 2 1992 135-9 487 13499132 JOURNAL ARTICLE LENKE D [Pharmacological effects of phathalazine and phthalazone derivatives. I]. Arzneimittelforschung 7 11 1957 678-81 488 13757612 JOURNAL ARTICLE KOHOUT J, KORBOVA L, BLAZEK K [Effect of anthistaminic drugs on the appearance of experimental gastric ulcer. III. Effect of mephenhydramine (alphadril) and polydroxyethylenesorbitanmonooleate on the appearance of gastric ulcers in guinea pigs]. Cas. Lek. Cesk. 100 1961 905-9 489 17404836 JOURNAL ARTICLE Ramadan ZB, Wrang ML, Tipton KF Species differences in the selective inhibition of monoamine oxidase (1-methyl-2-phenylethyl)hydrazine and its potentiation by cyanide. Neurochem. Res. 32 10 2007 1783-90 490 5889715 JOURNAL ARTICLE Gilmour SJ Clinical trial of mebanazine--a new monoamine oxidase inhibitor. Br J Psychiatry 111 478 1965 899-902 491 19582593 10.1007/s12013-009-9057-4 JOURNAL ARTICLE Uebele VN, Nuss CE, Fox SV, Garson SL, Cristescu R, Doran SM, Kraus RL, Santarelli VP, Li Y, Barrow JC, Yang ZQ, Schlegel KA, Rittle KE, Reger TS, Bednar RA, Lemaire W, Mullen FA, Ballard JE, Tang C, Dai G, McManus OB, Koblan KS, Renger JJ Positive allosteric interaction of structurally diverse T-type calcium channel antagonists. Cell Biochem. Biophys. 55 2 2009 81-93 492 15931571 JOURNAL ARTICLE Brown WM Taltirelin (Tanabe Seiyaku). IDrugs 4 12 2001 1389-400 493 BLA:761035 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/761035s000lbl.pdf 2015 494 15306801 JOURNAL ARTICLE Voets T, Droogmans G, Wissenbach U, Janssens A, Flockerzi V, Nilius B The principle of temperature-dependent gating in cold- and heat-sensitive TRP channels. Nature 430 7001 2004 748-54 495 18305010 10.1124/jpet.108.136960 JOURNAL ARTICLE Ehlert FJ, Griffin MT Two-state models and the analysis of the allosteric effect of gallamine at the M2 muscarinic receptor. J. Pharmacol. Exp. Ther. 325 3 2008 1039-60 496 18258787 10.1096/fj.07-099424 JOURNAL ARTICLE Shorter K, Farjo NP, Picksley SM, Randall VA Human hair follicles contain two forms of ATP-sensitive potassium channels, only one of which is sensitive to minoxidil. FASEB J. 22 6 2008 1725-36 497 8680742 JOURNAL ARTICLE Prior C, Tian L, el Mallah AI, Young L, Ward JM Neuromuscular blocking profile of the vecuronium analogue, Org-9487, in the rat isolated hemidiaphragm preparation. Br. J. Pharmacol. 116 7 1995 3049-55 498 7551370 JOURNAL ARTICLE Hozawa S, Haruta Y, Ishioka S, Yamakido M Effects of a PAF antagonist, Y-24180, on bronchial hyperresponsiveness in patients with asthma. Am. J. Respir. Crit. Care Med. 152 4 Pt 1 1995 1198-202 500 NDA:020212 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf 2014 501 17705685 JOURNAL ARTICLE Gille A, Bodor ET, Ahmed K, Offermanns S Nicotinic acid: pharmacological effects and mechanisms of action. Annu. Rev. Pharmacol. Toxicol. 48 2008 79-106 502 NDA:020766 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020766s035lbl.pdf 2015 503 NDA:208434 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/208434s000lbl.pdf 2015 504 25349307 10.1158/1535-7163.MCT-14-0274 JOURNAL ARTICLE Kodama T, Tsukaguchi T, Satoh Y, Yoshida M, Watanabe Y, Kondoh O, Sakamoto H Alectinib shows potent antitumor activity against RET-rearranged non-small cell lung cancer. Mol. Cancer Ther. 13 12 2014 2910-8 505 NDA:020576 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020576s010lbl.pdf 2010 506 26291199 10.1021/acs.jmedchem.5b00698 JOURNAL ARTICLE Asaki T, Kuwano K, Morrison K, Gatfield J, Hamamoto T, Clozel M Selexipag: An Oral and Selective IP Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial Hypertension. J. Med. Chem. 58 18 2015 7128-37 507 NDA:207947 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207947s000lbl.pdf 2015 508 NDA:207988 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207988lbl.pdf 2015 509 17276408 JOURNAL ARTICLE Triggle DJ Calcium channel antagonists: clinical uses--past, present and future. Biochem. Pharmacol. 74 1 2007 1-9 510 10487332 JOURNAL ARTICLE Timmermans PB Angiotensin II receptor antagonists: an emerging new class of cardiovascular therapeutics. Hypertens. Res. 22 2 1999 147-53 511 1666418 JOURNAL ARTICLE Kubo M, Ochiai T, Kato J, Ishida R Pharmacological studies on TA-6366, a new ACE inhibitor: II. Effect of long-term administration from the pre-hypertensive stage on blood pressure, relative heart weight and ACE activity of various tissues in spontaneously hypertensive rats (SHRs). Jpn. J. Pharmacol. 57 4 1991 517-26 512 22047812 10.1016/j.clinthera.2011.09.023 JOURNAL ARTICLE Kim JW, Kim JR, Yi S, Shin KH, Shin HS, Yoon SH, Cho JY, Kim DH, Shin SG, Jang IJ, Yu KS Tolerability and pharmacokinetics of lobeglitazone (CKD-501), a peroxisome proliferator-activated receptor-γ agonist: a single- and multiple-dose, double-blind, randomized control study in healthy male Korean subjects. Clin Ther 33 11 2011 1819-30 513 8872297 JOURNAL ARTICLE Ziegler D, Haxhiu MA, Kaan EC, Papp JG, Ernsberger P Pharmacology of moxonidine, an I1-imidazoline receptor agonist. J. Cardiovasc. Pharmacol. 27 Suppl 3 1996 S26-37 514 15716462 JOURNAL ARTICLE Fagart J, Seguin C, Pinon GM, Rafestin-Oblin ME The Met852 residue is a key organizer of the ligand-binding cavity of the human mineralocorticoid receptor. Mol. Pharmacol. 67 5 2005 1714-22 515 21771637 10.1016/j.mce.2011.06.025 JOURNAL ARTICLE Kolkhof P, Borden SA Molecular pharmacology of the mineralocorticoid receptor: prospects for novel therapeutics. Mol. Cell. Endocrinol. 350 2 2012 310-7 516 19833635 10.1093/jac/dkp370 JOURNAL ARTICLE Chen YH, Liu CY, Lu JJ, King CH, Hsueh PR In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan. J. Antimicrob. Chemother. 64 6 2009 1226-9 517 12173241 JOURNAL ARTICLE Scholz A Mechanisms of (local) anaesthetics on voltage-gated sodium and other ion channels. Br J Anaesth 89 1 2002 52-61 518 NDA:201444 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/201444s000lbl.pdf 2011 519 7763301 JOURNAL ARTICLE Coley HM, Brooks N, Phillips DH, Hewer A, Jenkins TC, Jarman M, Judson IR The role of the N-(hydroxymethyl)melamines as antitumour agents: mechanism of action studies. Biochem. Pharmacol. 49 9 1995 1203-12 520 6200290 JOURNAL ARTICLE Richards DM, Brogden RN, Heel RC, Speight TM, Avery GS Oxatomide. A review of its pharmacodynamic properties and therapeutic efficacy. Drugs 27 3 1984 210-31 521 NDA:050778 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050778s021lbl.pdf 2014 522 NDA:020645 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020645s008lbl.pdf 2011 523 NDA:019998 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019998s013lbl.pdf 2007 524 NDA:008922 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/008922s016lbl.pdf 2009 525 NDA:021749 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021749s008lbl.pdf 2013 526 NDA:022252 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022252s004lbl.pdf 2015 527 mepronizine_ct_8952 DRUG LABEL http://www.has-sante.fr/portail/upload/docs/application/pdf/2012-09/mepronizine_ct_8952.pdf 2011 528 15740719 JOURNAL ARTICLE Gimpl G, Postina R, Fahrenholz F, Reinheimer T Binding domains of the oxytocin receptor for the selective oxytocin receptor antagonist barusiban in comparison to the agonists oxytocin and carbetocin. Eur. J. Pharmacol. 510 1-2 2005 9-16 529 CP-2015-PI-01665-1 DRUG LABEL https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2015-PI-01665-1 2015 444 9368911 JOURNAL ARTICLE Bruhwyler J, Liégeois JF, Géczy J Pirlindole: a selective reversible inhibitor of monoamine oxidase A. A review of its preclinical properties. Pharmacol. Res. 36 1 1997 23-33 445 12781338 JOURNAL ARTICLE Hynson RM, Wouters J, Ramsay RR Monoamine oxidase A inhibitory potency and flavin perturbation are influenced by different aspects of pirlindole inhibitor structure. Biochem. Pharmacol. 65 11 2003 1867-74 446 24900486 10.1021/ml300049d JOURNAL ARTICLE Rice KD, Aay N, Anand NK, Blazey CM, Bowles OJ, Bussenius J, Costanzo S, Curtis JK, Defina SC, Dubenko L, Engst S, Joshi AA, Kennedy AR, Kim AI, Koltun ES, Lougheed JC, Manalo JC, Martini JF, Nuss JM, Peto CJ, Tsang TH, Yu P, Johnston S Novel Carboxamide-Based Allosteric MEK Inhibitors: Discovery and Optimization Efforts toward XL518 (GDC-0973). ACS Med Chem Lett 3 5 2012 416-21 447 18506437 10.1007/s00228-008-0478-6 JOURNAL ARTICLE Sahasranaman S, Howard D, Roy S Clinical pharmacology and pharmacogenetics of thiopurines. Eur. J. Clin. Pharmacol. 64 8 2008 753-67 448 26171220 10.1002/prp2.136 JOURNAL ARTICLE Jain MR, Giri SR, Trivedi C, Bhoi B, Rath A, Vanage G, Vyas P, Ranvir R, Patel PR Saroglitazar, a novel PPARα/γ agonist with predominant PPARα activity, shows lipid-lowering and insulin-sensitizing effects in preclinical models. Pharmacol Res Perspect 3 3 2015 e00136 449 17005916 JOURNAL ARTICLE Ligneau X, Perrin D, Landais L, Camelin JC, Calmels TP, Berrebi-Bertrand I, Lecomte JM, Parmentier R, Anaclet C, Lin JS, Bertaina-Anglade V, la Rochelle CD, d'Aniello F, Rouleau A, Gbahou F, Arrang JM, Ganellin CR, Stark H, Schunack W, Schwartz JC BF2.649 [1-{3-[3-(4-Chlorophenyl)propoxy]propyl}piperidine, hydrochloride], a nonimidazole inverse agonist/antagonist at the human histamine H3 receptor: Preclinical pharmacology. J. Pharmacol. Exp. Ther. 320 1 2007 365-75 450 21615387 10.1111/j.1476-5381.2011.01286.x JOURNAL ARTICLE Schwartz JC The histamine H3 receptor: from discovery to clinical trials with pitolisant. Br. J. Pharmacol. 163 4 2011 713-21 451 BLA:125338 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125338s085s087s088lbl.pdf 2015 452 NDA:021877 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021877s005lbl.pdf 2012 453 3207986 JOURNAL ARTICLE Thijssen HH, Baars LG, Vervoort-Peters HT Vitamin K 2,3-epoxide reductase: the basis for stereoselectivity of 4-hydroxycoumarin anticoagulant activity. Br. J. Pharmacol. 95 3 1988 675-82 454 NDA:207533 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207533s000lbl.pdf 2015 369 NDA:017588 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/017588s040lbl.pdf 2014 455 16251241 JOURNAL ARTICLE Wikström B, Gellert R, Ladefoged SD, Danda Y, Akai M, Ide K, Ogasawara M, Kawashima Y, Ueno K, Mori A, Ueno Y Kappa-opioid system in uremic pruritus: multicenter, randomized, double-blind, placebo-controlled clinical studies. J. Am. Soc. Nephrol. 16 12 2005 3742-7 456 22084396 10.1158/0008-5472.CAN-11-1515 JOURNAL ARTICLE Hoeflich KP, Merchant M, Orr C, Chan J, Den Otter D, Berry L, Kasman I, Koeppen H, Rice K, Yang NY, Engst S, Johnston S, Friedman LS, Belvin M Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition. Cancer Res. 72 1 2012 210-9 457 NDA:020706 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/20706slr011_emadine_lbl.pdf 2003 458 24660890 10.1021/jm401992e JOURNAL ARTICLE Biftu T, Sinha-Roy R, Chen P, Qian X, Feng D, Kuethe JT, Scapin G, Gao YD, Yan Y, Krueger D, Bak A, Eiermann G, He J, Cox J, Hicks J, Lyons K, He H, Salituro G, Tong S, Patel S, Doss G, Petrov A, Wu J, Xu SS, Sewall C, Zhang X, Zhang B, Thornberry NA, Weber AE Omarigliptin (MK-3102): a novel long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetes. J. Med. Chem. 57 8 2014 3205-12 459 NDA:205739 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205739s000lbl.pdf 2015 460 NDA:021882 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021882s021lbl.pdf 2015 461 NDA:207953 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207953s000lbl.pdf 2015 462 NDA:021629 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021629s030lbl.pdf 2015 463 1387020 JOURNAL ARTICLE Yamamura Y, Ogawa H, Yamashita H, Chihara T, Miyamoto H, Nakamura S, Onogawa T, Yamashita T, Hosokawa T, Mori T Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist. Br. J. Pharmacol. 105 4 1992 787-91 464 9469684 JOURNAL ARTICLE Brown LA, Levin GM Sertindole, a new atypical antipsychotic for the treatment of schizophrenia. Pharmacotherapy 18 1 69-83 465 10991983 JOURNAL ARTICLE Herrick-Davis K, Grinde E, Teitler M Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors. J. Pharmacol. Exp. Ther. 295 1 2000 226-32 466 11855658 JOURNAL ARTICLE Endoh M Mechanism of action of Ca2+ sensitizers--update 2001. Cardiovasc Drugs Ther 15 5 2001 397-403 467 10644512 JOURNAL ARTICLE Nagumo H, Sasaki Y, Ono Y, Okamoto H, Seto M, Takuwa Y Rho kinase inhibitor HA-1077 prevents Rho-mediated myosin phosphatase inhibition in smooth muscle cells. Am. J. Physiol., Cell Physiol. 278 1 2000 C57-65 468 10.1016/S0168-8278(14)61094-1 JOURNAL ARTICLE N. Izumi, R. Tateishi, M. Seike, M. Kudo, H. Tamai, S. Kawazoe, K. Tanaka, M. Kurokawa, Y. Osaki, K. Yamamoto, M. Imawari P933 ONCE-DAILY ORAL LUSUTROMBOPAG, ALTERNATIVE TO PLATELET TRANSFUSION IN THROMBOCYTOPENIC PATIENTS WITH CHRONIC LIVER DISEASE UNDERGOING RADIOFREQUENCY ABLATION: RESULTS FROM A PHASE 2B, RANDOMIZED, DOUBLE-BLIND STUDY 0168-8278 http://www.sciencedirect.com/science/article/pii/S0168827814610941 Journal of Hepatology 60 1 2014 S386 469 BLA:125526 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125526Orig1s000Lbl.pdf 2015 470 17652911 JOURNAL ARTICLE Hirata T, Keto Y, Funatsu T, Akuzawa S, Sasamata M Evaluation of the pharmacological profile of ramosetron, a novel therapeutic agent for irritable bowel syndrome. J. Pharmacol. Sci. 104 3 2007 263-73 471 19967488 10.1007/s10147-009-0912-5 JOURNAL ARTICLE Ayuhara H, Takayanagi R, Okuyama K, Yoshimoto K, Ozeki T, Yokoyama H, Yamada Y Receptor occupancy theory-based analysis of interindividual differences in antiemetic effects of 5-HT3 receptor antagonists. Int. J. Clin. Oncol. 14 6 2009 518-24 472 1397053 JOURNAL ARTICLE Boeijinga PH, Galvan M, Baron BM, Dudley MW, Siegel BW, Slone AL Characterization of the novel 5-HT3 antagonists MDL 73147EF (dolasetron mesilate) and MDL 74156 in NG108-15 neuroblastoma x glioma cells. Eur. J. Pharmacol. 219 1 1992 9-13 473 25271963 10.1021/jm500973a JOURNAL ARTICLE Finlay MR, Anderton M, Ashton S, Ballard P, Bethel PA, Box MR, Bradbury RH, Brown SJ, Butterworth S, Campbell A, Chorley C, Colclough N, Cross DA, Currie GS, Grist M, Hassall L, Hill GB, James D, James M, Kemmitt P, Klinowska T, Lamont G, Lamont SG, Martin N, McFarland HL, Mellor MJ, Orme JP, Perkins D, Perkins P, Richmond G, Smith P, Ward RA, Waring MJ, Whittaker D, Wells S, Wrigley GL Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor. J. Med. Chem. 57 20 2014 8249-67 474 NDA:208065 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/208065s000lbl.pdf 2015 475 15123680 JOURNAL ARTICLE Fu T, Mukhopadhyay D, Davidson NO, Borensztajn J The peroxisome proliferator-activated receptor alpha (PPARalpha) agonist ciprofibrate inhibits apolipoprotein B mRNA editing in low density lipoprotein receptor-deficient mice: effects on plasma lipoproteins and the development of atherosclerotic lesions. J. Biol. Chem. 279 27 2004 28662-9 476 9405293 JOURNAL ARTICLE Bowker-Kinley MM, Davis WI, Wu P, Harris RA, Popov KM Evidence for existence of tissue-specific regulation of the mammalian pyruvate dehydrogenase complex. Biochem. J. 329 ( Pt 1) 1998 191-6 415 1546145 JOURNAL ARTICLE Dingemanse J, Berlin I, Payan C, Thiede HM, Puech AJ Comparative investigation of the effect of moclobemide and toloxatone on monoamine oxidase activity and psychometric performance in healthy subjects. Psychopharmacology (Berl.) 106 Suppl 1992 S68-70 416 12177684 JOURNAL ARTICLE Borsini F, Evans K, Jason K, Rohde F, Alexander B, Pollentier S Pharmacology of flibanserin. CNS Drug Rev 8 2 2002 117-42 417 NDA:022526 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022526lbl.pdf 2015 418 20840530 10.1111/j.1743-6109.2010.02032.x JOURNAL ARTICLE Stahl SM, Sommer B, Allers KA Multifunctional pharmacology of flibanserin: possible mechanism of therapeutic action in hypoactive sexual desire disorder. J Sex Med 8 1 2011 15-27 420 7878037 JOURNAL ARTICLE Double KL, Crocker AD Dopamine receptors in the substantia nigra are involved in the regulation of muscle tone. Proc. Natl. Acad. Sci. U.S.A. 92 5 1995 1669-73 423 12480161 JOURNAL ARTICLE Liu YC, Lo YK, Wu SN Stimulatory effects of chlorzoxazone, a centrally acting muscle relaxant, on large conductance calcium-activated potassium channels in pituitary GH3 cells. Brain Res. 959 1 2003 86-97 424 16004599 JOURNAL ARTICLE Jenner P Istradefylline, a novel adenosine A2A receptor antagonist, for the treatment of Parkinson's disease. Expert Opin Investig Drugs 14 6 2005 729-38 425 BLA:103694 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/103694s1008lbl.pdf 2009 426 20209107 10.1371/journal.pone.0009430 JOURNAL ARTICLE Humbert M, Castéran N, Letard S, Hanssens K, Iovanna J, Finetti P, Bertucci F, Bader T, Mansfield CD, Moussy A, Hermine O, Dubreuil P Masitinib combined with standard gemcitabine chemotherapy: in vitro and in vivo studies in human pancreatic tumour cell lines and ectopic mouse model. PLoS ONE 5 3 2010 e9430 427 NDA:020572 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020572s016,020573s015lbl.pdf 2009 428 NDA:009048 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/09048slr037_methoxsalen_lbl.pdf 2003 429 11556519 JOURNAL ARTICLE Henrotin Y, de Leval X, Mathy-Hartet M, Mouithys-Mickalad A, Deby-Dupont G, Dogné JM, Delarge J, Reginster JY In vitro effects of aceclofenac and its metabolites on the production by chondrocytes of inflammatory mediators. Inflamm. Res. 50 8 2001 391-9 430 22497992 10.1016/j.pbb.2012.03.021 JOURNAL ARTICLE Duffy RA, Morgan C, Naylor R, Higgins GA, Varty GB, Lachowicz JE, Parker EM Rolapitant (SCH 619734): a potent, selective and orally active neurokinin NK1 receptor antagonist with centrally-mediated antiemetic effects in ferrets. Pharmacol. Biochem. Behav. 102 1 2012 95-100 431 NDA:206500 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206500s000lbl.pdf 2015 432 EMEA/H/C/004004 DRUG LABEL http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004004/WC500192715.pdf 2015 433 2001448 JOURNAL ARTICLE Gasson JC Molecular physiology of granulocyte-macrophage colony-stimulating factor. Blood 77 6 1991 1131-45 434 BLA:125141 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125141s219lbl.pdf 2014 435 22686619 10.2165/11631090-000000000-00000 JOURNAL ARTICLE Subramaniam JM, Whiteside G, McKeage K, Croxtall JC Mogamulizumab: first global approval. Drugs 72 9 2012 1293-8 436 NDA:021665 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021665s005lbl.pdf 2012 437 17234181 JOURNAL ARTICLE Mascia MP, Bachis E, Obili N, Maciocco E, Cocco GA, Sechi GP, Biggio G Thiocolchicoside inhibits the activity of various subtypes of recombinant GABA(A) receptors expressed in Xenopus laevis oocytes. Eur. J. Pharmacol. 558 1-3 2007 37-42 438 26056160 10.1124/mol.115.099291 JOURNAL ARTICLE Hammer H, Bader BM, Ehnert C, Bundgaard C, Bunch L, Hoestgaard-Jensen K, Schroeder OH, Bastlund JF, Gramowski-Voß A, Jensen AA A Multifaceted GABAA Receptor Modulator: Functional Properties and Mechanism of Action of the Sedative-Hypnotic and Recreational Drug Methaqualone (Quaalude). Mol. Pharmacol. 88 2 2015 401-20 439 20093397 10.1124/jpet.109.160432 JOURNAL ARTICLE Kiss B, Horváth A, Némethy Z, Schmidt E, Laszlovszky I, Bugovics G, Fazekas K, Hornok K, Orosz S, Gyertyán I, Agai-Csongor E, Domány G, Tihanyi K, Adham N, Szombathelyi Z Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile. J. Pharmacol. Exp. Ther. 333 1 2010 328-40 440 NDA:204370 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/204370lbl.pdf 2015 441 6285914 JOURNAL ARTICLE Rosenfeld RG, Aggarwal BB, Hintz RL, Dollar LA Recombinant DNA-derived methionyl human growth hormone is similar in membrane binding properties to human pituitary growth hormone. Biochem. Biophys. Res. Commun. 106 1 1982 202-9 442 NDA:207981 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207981s000lbl.pdf 2015 443 8891469 JOURNAL ARTICLE Noble S, McTavish D Reteplase. A review of its pharmacological properties and clinical efficacy in the management of acute myocardial infarction. Drugs 52 4 1996 589-605 397 NDA:019853 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/19853s012,014lbl.pdf 2004 398 6121964 JOURNAL ARTICLE Walshe JM Treatment of Wilson's disease with trientine (triethylene tetramine) dihydrochloride. Lancet 1 8273 1982 643-7 399 10102460 JOURNAL ARTICLE Eriksson H, Eriksson UG, Frison L, Hansson PO, Held P, Holmström M, Hägg A, Jonsson T, Lapidus L, Leijd B, Stockelberg D, Säfwenberg U, Taghavi A, Thorsén M Pharmacokinetics and pharmacodynamics of melagatran, a novel synthetic LMW thrombin inhibitor, in patients with acute DVT. Thromb. Haemost. 81 3 1999 358-63 400 NDA:022037 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022037s011lbl.pdf 2015 401 22633824 10.1016/S0140-6736(12)60771-5 JOURNAL ARTICLE Stein EA, Gipe D, Bergeron J, Gaudet D, Weiss R, Dufour R, Wu R, Pordy R Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet 380 9836 2012 29-36 402 BLA:103950 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/103950s5150lbl.pdf 2013 403 BLA:125559 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125559Orig1s000lbl.pdf 2015 404 9205952 JOURNAL ARTICLE Alvarez-Guerra M, Alda O, Garay RP Celiprolol: agonist and antagonist effects at cardiac beta 1- and vascular beta 2-adrenoceptors determined under in vivo conditions in the rat. Naunyn Schmiedebergs Arch. Pharmacol. 355 6 1997 689-98 405 BLA:103979 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/103979s5135lbl.pdf 2010 406 WOS:A1990DP01300004 JOURNAL ARTICLE CAROPPO, R EFFECT OF NIPEROTIDINE ON HYDROGEN-ION SECRETION AND ELECTRICAL PARAMETERS OF ISOLATED ASTRIC-MUCOSA Curr. Ther. Res.-Clin. Exp. 48 1 1990 20-29 407 EMEA/H/C/000369 DRUG LABEL http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000369/WC500053612.pdf 2015 408 NDA:204760 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204760s000lbl.pdf 2014 409 22037049 10.1016/j.bmc.2011.10.007 JOURNAL ARTICLE Lewin AH, Miller GM, Gilmour B Trace amine-associated receptor 1 is a stereoselective binding site for compounds in the amphetamine class. Bioorg. Med. Chem. 19 23 2011 7044-8 410 NDA:016419 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/016419s029lbl.pdf 2008 411 2139412 JOURNAL ARTICLE Santen RJ, Langecker P, Santner SJ, Sikka S, Rajfer J, Swerdloff R Potency and specificity of CGS-16949A as an aromatase inhibitor. Endocr. Res. 16 1 1990 77-91 412 2521224 JOURNAL ARTICLE Santen RJ, Demers LM, Adlercreutz H, Harvey H, Santner S, Sanders S, Lipton A Inhibition of aromatase with CGS 16949A in postmenopausal women. J. Clin. Endocrinol. Metab. 68 1 1989 99-106 413 NDA:019385 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/19385slr030,031,035_permax_lbl.pdf 2003 383 26131937 10.1038/nature14610 JOURNAL ARTICLE Krönke J, Fink EC, Hollenbach PW, MacBeth KJ, Hurst SN, Udeshi ND, Chamberlain PP, Mani DR, Man HW, Gandhi AK, Svinkina T, Schneider RK, McConkey M, Järås M, Griffiths E, Wetzler M, Bullinger L, Cathers BE, Carr SA, Chopra R, Ebert BL Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS. Nature 2015 "" 384 NDA:207620 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207620Orig1s000lbl.pdf 2015 385 1101049 JOURNAL ARTICLE Youdim MB Monoamine oxidase. Its inhibition. Mod Probl Pharmacopsychiatry 10 1975 65-88 386 21186796 10.1021/jm101016w JOURNAL ARTICLE Zhang Z, Wallace MB, Feng J, Stafford JA, Skene RJ, Shi L, Lee B, Aertgeerts K, Jennings A, Xu R, Kassel DB, Kaldor SW, Navre M, Webb DR, Gwaltney SL Design and synthesis of pyrimidinone and pyrimidinedione inhibitors of dipeptidyl peptidase IV. J. Med. Chem. 54 2 2011 510-24 387 26115728 JOURNAL ARTICLE McKeage K Trelagliptin: First Global Approval. Drugs 2015 "" 388 11786663 JOURNAL ARTICLE Fukushima Y, Otsuka H, Ishikawa M, Asano T, Anai M, Katsube T, Ogawa K, Kajiwara T, Ohkawa S, Ishikawa T, Omata M, Saitoh T Potent and long-lasting action of lafutidine on the human histamine H(2) receptor. Digestion 64 3 2001 155-60 389 7703232 JOURNAL ARTICLE Lotta T, Vidgren J, Tilgmann C, Ulmanen I, Melén K, Julkunen I, Taskinen J Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry 34 13 1995 4202-10 390 11160603 JOURNAL ARTICLE Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, Rogers MJ Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J. Pharmacol. Exp. Ther. 296 2 2001 235-42 391 24947465 10.1124/jpet.114.213793 JOURNAL ARTICLE Maeda K, Sugino H, Akazawa H, Amada N, Shimada J, Futamura T, Yamashita H, Ito N, McQuade RD, Mørk A, Pehrson AL, Hentzer M, Nielsen V, Bundgaard C, Arnt J, Stensbøl TB, Kikuchi T Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. J. Pharmacol. Exp. Ther. 350 3 2014 589-604 392 NDA:205422 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205422s000lbl.pdf 2015 393 NDA:021106 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021106s036lbl.pdf 2013 395 20600305 10.1016/j.pharmthera.2010.06.002 JOURNAL ARTICLE Millan MJ From the cell to the clinic: a comparative review of the partial D₂/D₃receptor agonist and α2-adrenoceptor antagonist, piribedil, in the treatment of Parkinson's disease. Pharmacol. Ther. 128 2 2010 229-73 396 15646370 JOURNAL ARTICLE Doi N, Hirotani C, Ukai K, Shimada O, Okuno T, Kurasaki S, Kiyofuji T, Ikegami R, Futamata M, Nakagawa T, Ase K, Chihara K Pharmacological characteristics of KP-102 (GHRP-2), a potent growth hormone-releasing peptide. Arzneimittelforschung 54 12 2004 857-67 279 21668582 10.1111/j.1349-7006.2011.02004.x JOURNAL ARTICLE Sakata K, Someya M, Matsumoto Y, Tauchi H, Kai M, Toyota M, Takagi M, Hareyama M, Fukushima M Gimeracil, an inhibitor of dihydropyrimidine dehydrogenase, inhibits the early step in homologous recombination. Cancer Sci. 102 9 2011 1712-6 280 3114201 JOURNAL ARTICLE Tatsumi K, Fukushima M, Shirasaka T, Fujii S Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts. Jpn. J. Cancer Res. 78 7 1987 748-55 281 8862723 JOURNAL ARTICLE Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K, Fukushima M Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 7 5 1996 548-57 282 NDA:020637 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020637s026lbl.pdf 2013 283 2858236 JOURNAL ARTICLE Dukes ID, Vaughan Williams EM Cardiovascular effects of bevantolol, a selective beta 1-adrenoceptor antagonist with a novel pharmacological profile. Br. J. Pharmacol. 84 2 1985 365-80 284 3924048 JOURNAL ARTICLE Bitonti AJ, Bacchi CJ, McCann PP, Sjoerdsma A Catalytic irreversible inhibition of Trypanosoma brucei brucei ornithine decarboxylase by substrate and product analogs and their effects on murine trypanosomiasis. Biochem. Pharmacol. 34 10 1985 1773-7 285 21651906 10.1016/j.ejphar.2011.05.049 JOURNAL ARTICLE Kawachi M, Matsunaga Y, Tanaka T, Hori Y, Ito K, Nagahama K, Ozaki T, Inoue N, Toda R, Yoshii K, Hirayama M, Kawabata Y, Takei M Acotiamide hydrochloride (Z-338) enhances gastric motility and emptying by inhibiting acetylcholinesterase activity in rats. Eur. J. Pharmacol. 666 1-3 2011 218-25 286 NDA:022249 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022249Orig1s019lbl.pdf 2015 288 9726653 JOURNAL ARTICLE Fujimoto S, Ohashi M, Hiramoto A, Inoue Y, Nagai K, Shiokawa H, Itoh T Vasorelaxant effect of olprinone, an inhibitor of phosphodiesterase 3, on mesenteric small artery and vein of rabbits. Eur. J. Pharmacol. 353 2-3 1998 239-46 289 NDA:206334 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206334s000lbl.pdf 2014 290 NDA:022011 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022011s013lbl.pdf 2013 291 8723169 JOURNAL ARTICLE Abou-Mohamed G, Nagarajan R, Ibrahim TM, Caldwell RW Characterization of the adrenergic activity of arbutamine, a novel agent for pharmacological stress testing. Cardiovasc Drugs Ther 10 1 1996 39-47 292 NDA:021476 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021476s030lbl.pdf 2014 293 6114717 JOURNAL ARTICLE Van Wauwe J, Awouters F, Neimegeers CJ, Janssens F, Van Nueten JM, Janssen PA In vivo pharmacology of astemizole, a new type of H1-antihistaminic compound. Arch Int Pharmacodyn Ther 251 1 1981 39-51 294 NDA:206333 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206333Orig1s000lbl.pdf 2015 295 NDA:022575 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022575s012lbl.pdf 2013 296 BLA:125427 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125427s033lbl.pdf 2014 297 NDA:205123 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205123s008lbl.pdf 2015 298 BLA:125103 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125103s146lbl.pdf 2013 299 EMEA/H/C/002556 DRUG LABEL http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002556/WC500148380.pdf 2015 300 23940628 10.1371/journal.pone.0070690 JOURNAL ARTICLE Barrière DA, Mallet C, Blomgren A, Simonsen C, Daulhac L, Libert F, Chapuy E, Etienne M, Högestätt ED, Zygmunt PM, Eschalier A Fatty acid amide hydrolase-dependent generation of antinociceptive drug metabolites acting on TRPV1 in the brain. PLoS ONE 8 8 2013 e70690 301 21828261 10.1124/jpet.111.185314 JOURNAL ARTICLE Shin JM, Inatomi N, Munson K, Strugatsky D, Tokhtaeva E, Vagin O, Sachs G Characterization of a novel potassium-competitive acid blocker of the gastric H,K-ATPase, 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438). J. Pharmacol. Exp. Ther. 339 2 2011 412-20 302 BLA:103946 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/103946s5083lbl.pdf 2009 303 NDA:019627 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/019627s062lbl.pdf 2014 304 NDA:022393 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022393s013lbl.pdf 2014 305 NDA:017808 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/017808s036lbl.pdf 2015 306 NDA:021999 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021999s029lbl.pdf 2014 307 1696381 JOURNAL ARTICLE Fujii M, Okabayashi Y, Nakamura T, Tani S, Fujisawa T, Otsuki M Action of a new cholinergic agonist, aclatonium napadisilate, on isolated rat pancreatic acini. Pancreas 5 4 1990 427-33 308 ANDA:083220 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/083220s041lbl.pdf 2005 309 15300AMZ00256000 DRUG LABEL http://eisai.jp/medical/products/di/EPI/CSP_C_EPI.pdf 2007 310 EMEA/H/C/002055 DRUG LABEL http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002055/WC500127968.pdf 2014 311 NDA:021029 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s028lbl.pdf 2015 312 NDA:021468 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021468s019lbl.pdf 2014 313 NDA:021179 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021179Orig1s030lbl.pdf 2014 314 EMEA/H/C/002465 DRUG LABEL http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002465/WC500151313.pdf 2014 315 NDA:017563 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/017563s023,020222s005lbl.pdf 2014 316 NDA:021141 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2000/21176lbl.pdf 2000 317 NDA:203284 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/203284s001lbl.pdf 2014 318 NDA:021271 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021271s006lbl.pdf 2014 319 11740949 JOURNAL ARTICLE Castelli MP, Mocci I, Sanna AM, Gessa GL, Pani L (-)S amisulpride binds with high affinity to cloned dopamine D(3) and D(2) receptors. Eur. J. Pharmacol. 432 2-3 2001 143-7 320 6186851 JOURNAL ARTICLE Levine SN, Hollier B Aprindine inhibits calmodulin-stimulated phosphodiesterase and Ca-ATPase activities. J. Cardiovasc. Pharmacol. 5 1 151-6 321 BLA:125151 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125151s0184lbl.pdf 2013 322 BLA:103234 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/103234s5323lbl.pdf 2013 323 BLA:125268 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125268s141lbl.pdf 2014 324 BLA:125058 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125058s220lbl.pdf 2013 325 NDA:021959 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021959s004lbl.pdf 2010 326 BLA:125460 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125460s000lbl.pdf 2014 327 12825935 JOURNAL ARTICLE Renaud J, Bischoff SF, Buhl T, Floersheim P, Fournier B, Halleux C, Kallen J, Keller H, Schlaeppi JM, Stark W Estrogen receptor modulators: identification and structure-activity relationships of potent ERalpha-selective tetrahydroisoquinoline ligands. J. Med. Chem. 46 14 2003 2945-57 328 22671931 10.1111/j.1476-5381.2012.02068.x JOURNAL ARTICLE Wade PR, Palmer JM, McKenney S, Kenigs V, Chevalier K, Moore BA, Mabus JR, Saunders PR, Wallace NH, Schneider CR, Kimball ES, Breslin HJ, He W, Hornby PJ Modulation of gastrointestinal function by MuDelta, a mixed µ opioid receptor agonist/ µ opioid receptor antagonist. Br. J. Pharmacol. 167 5 2012 1111-25 329 NDA:022572 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022572s003lbl.pdf 2014 330 NDA:020563 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020563s124lbl.pdf 2015 331 NDA:206940 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206940s000lbl.pdf 2015 332 NDA:018780 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/018780s150lbl.pdf 2015 333 23083772 10.1016/j.jacc.2012.08.986 JOURNAL ARTICLE Dias CS, Shaywitz AJ, Wasserman SM, Smith BP, Gao B, Stolman DS, Crispino CP, Smirnakis KV, Emery MG, Colbert A, Gibbs JP, Retter MW, Cooke BP, Uy ST, Matson M, Stein EA Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins. J. Am. Coll. Cardiol. 60 19 2012 1888-98 334 EMEA/H/C/000885 DRUG LABEL http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000885/WC500052310.pdf 2015 335 26518 JOURNAL ARTICLE Galeone M, Moise G, Ferrante F, Cacioli D, Casula PL, Bignamini AA Double-blind clinical comparison between a gastrin-receptor antagonist, proglumide, and a histamine H2-blocker, cimetidine. Curr Med Res Opin 5 5 1978 376-82 336 2863192 JOURNAL ARTICLE Loewe CJ, Grider JR, Gardiner J, Vlahcevic ZR Selective inhibition of pentagastrin- and cholecystokinin-stimulated exocrine secretion by proglumide. Gastroenterology 89 4 1985 746-51 337 2299627 JOURNAL ARTICLE Freidinger RM, Whitter WL, Gould NP, Holloway MK, Chang RS, Lotti VJ Novel glutamic acid derived cholecystokinin receptor ligands. J. Med. Chem. 33 2 1990 591-5 370 28684 JOURNAL ARTICLE Falliers CJ, Redding MA, Katsampes CP Inhibition of cutaneous and mucosal allergy with phenyltoloxamine. Ann Allergy 41 3 1978 140-4 371 NDA:020718 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020718s037lbl.pdf 2013 267 EMEA/H/C/001012 DRUG LABEL http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001012/WC500053998.pdf 2014 338 17300164 JOURNAL ARTICLE Sturino CF, O'Neill G, Lachance N, Boyd M, Berthelette C, Labelle M, Li L, Roy B, Scheigetz J, Tsou N, Aubin Y, Bateman KP, Chauret N, Day SH, Lévesque JF, Seto C, Silva JH, Trimble LA, Carriere MC, Denis D, Greig G, Kargman S, Lamontagne S, Mathieu MC, Sawyer N, Slipetz D, Abraham WM, Jones T, McAuliffe M, Piechuta H, Nicoll-Griffith DA, Wang Z, Zamboni R, Young RN, Metters KM Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]-acetic acid (MK-0524). J. Med. Chem. 50 4 2007 794-806 339 25765567 10.1111/bph.13129 JOURNAL ARTICLE Nassini R, Fusi C, Materazzi S, Coppi E, Tuccinardi T, Marone IM, De Logu F, Preti D, Tonello R, Chiarugi A, Patacchini R, Geppetti P, Benemei S The TRPA1 channel mediates the analgesic action of dipyrone and pyrazolone derivatives. Br. J. Pharmacol. 2015 "" 340 25171227 10.1517/13543784.2014.956079 JOURNAL ARTICLE Sałat K, Jakubowska A, Kulig K Zucapsaicin for the treatment of neuropathic pain. Expert Opin Investig Drugs 23 10 2014 1433-40 341 BLA:125422 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125422s025lbl.pdf 2014 343 14681344 JOURNAL ARTICLE Yu KS, Bae KS, Shon JH, Cho JY, Yi SY, Chung JY, Lim HS, Jang IJ, Shin SG, Song KS, Moon BS Pharmacokinetic and pharmacodynamic evaluation of a novel proton pump inhibitor, YH1885, in healthy volunteers. J Clin Pharmacol 44 1 2004 73-82 344 18638004 10.1111/j.1743-6109.2008.00945.x JOURNAL ARTICLE Paick JS, Ahn TY, Choi HK, Chung WS, Kim JJ, Kim SC, Kim SW, Lee SW, Min KS, Moon KH, Park JK, Park K, Park NC, Suh JK, Yang DY, Jung HG Efficacy and safety of mirodenafil, a new oral phosphodiesterase type 5 inhibitor, for treatment of erectile dysfunction. J Sex Med 5 11 2008 2672-80 345 10.1002/jlcr.1116 JOURNAL ARTICLE Shin, Hyun-Il; Lee, Juyoung; Kim, Dae-Kee Synthesis of 5-​ethyl-​2-​{5-​[4-​(2-​hydroxyethyl)​piperazin-​1-​ylsulfonyl]​-​2-​n-​propoxyphenyl}​-​7-​n-​propyl-​3,​5-​dihydro-​4H-​pyrrolo[3,​2-​d]​-​[2-​14C]​pyrimidin-​4-​one.2 HCl (14C-​SK3530.2 HCl) J Labelled Comp Radiopharm. 49 13 2006 1141–1149 346 24995399 10.1111/cbdd.12390 JOURNAL ARTICLE Song W, Zhang X, Li S, Xu W Design, synthesis, and preliminary activity evaluation of novel pyrimidine derivatives as acid pump antagonists. Chem Biol Drug Des 85 3 2015 306-14 347 6422042 JOURNAL ARTICLE Sestanj K, Bellini F, Fung S, Abraham N, Treasurywala A, Humber L, Simard-Duquesne N, Dvornik D N-[5-(trifluoromethyl)-6-methoxy-1-naphthalenyl]thioxomethyl]- N-methylglycine (Tolrestat), a potent, orally active aldose reductase inhibitor. J. Med. Chem. 27 3 1984 255-6 348 10766174 JOURNAL ARTICLE Adjei AA, Erlichman C, Davis JN, Cutler DL, Sloan JA, Marks RS, Hanson LJ, Svingen PA, Atherton P, Bishop WR, Kirschmeier P, Kaufmann SH A Phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity. Cancer Res. 60 7 2000 1871-7 349 8536820 JOURNAL ARTICLE Göke B, Fuder H, Wieckhorst G, Theiss U, Stridde E, Littke T, Kleist P, Arnold R, Lücker PW Voglibose (AO-128) is an efficient alpha-glucosidase inhibitor and mobilizes the endogenous GLP-1 reserve. Digestion 56 6 1995 493-501 350 9792651 JOURNAL ARTICLE Cotte N, Balestre MN, Phalipou S, Hibert M, Manning M, Barberis C, Mouillac B Identification of residues responsible for the selective binding of peptide antagonists and agonists in the V2 vasopressin receptor. J. Biol. Chem. 273 45 1998 29462-8 352 NDA:206426 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206426lbl.pdf 2014 353 20530654 10.1124/jpet.110.168633 JOURNAL ARTICLE Gbahou F, Davenas E, Morisset S, Arrang JM Effects of betahistine at histamine H3 receptors: mixed inverse agonism/agonism in vitro and partial inverse agonism in vivo. J. Pharmacol. Exp. Ther. 334 3 2010 945-54 354 7692441 JOURNAL ARTICLE Chen R, Lewis KA, Perrin MH, Vale WW Expression cloning of a human corticotropin-releasing-factor receptor. Proc. Natl. Acad. Sci. U.S.A. 90 19 1993 8967-71 355 objectId=212 ONLINE RESOURCE Frank M. Dautzenberg, Dimitri E. Grigoriadis, Richard L. Hauger, Thomas Steckler, Wylie W. Vale. Corticotropin-releasing factor receptors: CRF1 receptor. Last modified on 02/02/2015. Accessed on 19/06/2015. IUPHAR/BPS Guide to PHARMACOLOGY http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=212 2015 356 21482695 10.1158/1535-7163.MCT-10-0792 JOURNAL ARTICLE Rivera VM, Squillace RM, Miller D, Berk L, Wardwell SD, Ning Y, Pollock R, Narasimhan NI, Iuliucci JD, Wang F, Clackson T Ridaforolimus (AP23573; MK-8669), a potent mTOR inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimens. Mol. Cancer Ther. 10 6 2011 1059-71 357 19536319 JOURNAL ARTICLE Ruhlmann C, Herrstedt J Casopitant: a novel NK(1)-receptor antagonist in the prevention of chemotherapy-induced nausea and vomiting. Ther Clin Risk Manag 5 2 2009 375-84 358 22805230 10.1097/WNF.0b013e31825a68c5 JOURNAL ARTICLE Sedehizadeh S, Keogh M, Maddison P The use of aminopyridines in neurological disorders. Clin Neuropharmacol 35 4 191-200 359 NDA:202799 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202799s001lbl.pdf 2012 360 23337758 10.1097/PPO.0b013e3182828d38 JOURNAL ARTICLE Cheetham P, Petrylak DP Tubulin-targeted agents including docetaxel and cabazitaxel. Cancer J 19 1 59-65 361 familyId=61 ONLINE RESOURCE Somatostatin receptors. Accessed on 19/06/2015. IUPHAR/BPS Guide to PHARMACOLOGY http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=61 2015 362 1828228 JOURNAL ARTICLE Demicheli C, Albertini JP, Garnier-Suillerot A Interaction of mithramycin with DNA. Evidence that mithramycin binds to DNA as a dimer in a right-handed screw conformation. Eur. J. Biochem. 198 2 1991 333-8 363 7527033 JOURNAL ARTICLE Smith BL, Bauer GB, Povirk LF DNA damage induced by bleomycin, neocarzinostatin, and melphalan in a precisely positioned nucleosome. Asymmetry in protection at the periphery of nucleosome-bound DNA. J. Biol. Chem. 269 48 1994 30587-94 364 11502873 JOURNAL ARTICLE Takasaki J, Kamohara M, Saito T, Matsumoto M, Matsumoto S, Ohishi T, Soga T, Matsushime H, Furuichi K Molecular cloning of the platelet P2T(AC) ADP receptor: pharmacological comparison with another ADP receptor, the P2Y(1) receptor. Mol. Pharmacol. 60 3 2001 432-9 365 NDA:204958 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/204958lbl.pdf 2015 366 EMEA/H/C/001033 DRUG LABEL http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001033/WC500043300.pdf 2015 367 NDA:021022 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21022s004lbl.pdf 2004 368 NDA:012911 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/012911Orig1s033lbl.pdf 2013 372 9315536 JOURNAL ARTICLE Phillips DR, Teng W, Arfsten A, Nannizzi-Alaimo L, White MM, Longhurst C, Shattil SJ, Randolph A, Jakubowski JA, Jennings LK, Scarborough RM Effect of Ca2+ on GP IIb-IIIa interactions with integrilin: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate. Circulation 96 5 1997 1488-94 373 020913 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020912s021,020913s018lbl.pdf 2015 374 1469694 JOURNAL ARTICLE Hartman GD, Egbertson MS, Halczenko W, Laswell WL, Duggan ME, Smith RL, Naylor AM, Manno PD, Lynch RJ, Zhang G Non-peptide fibrinogen receptor antagonists. 1. Discovery and design of exosite inhibitors. J. Med. Chem. 35 24 1992 4640-2 375 23063522 10.1016/j.bmc.2012.09.030 JOURNAL ARTICLE Wang J, Mook RA, Lu J, Gooden DM, Ribeiro A, Guo A, Barak LS, Lyerly HK, Chen W Identification of a novel Smoothened antagonist that potently suppresses Hedgehog signaling. Bioorg. Med. Chem. 20 22 2012 6751-7 376 22042473 10.1097/SLA.0b013e318236bc0f JOURNAL ARTICLE Fendrich V, Wiese D, Waldmann J, Lauth M, Heverhagen AE, Rehm J, Bartsch DK Hedgehog inhibition with the orally bioavailable Smo antagonist LDE225 represses tumor growth and prolongs survival in a transgenic mouse model of islet cell neoplasms. Ann. Surg. 254 5 2011 818-23; discussion 823 377 21073468 10.1111/j.1471-4159.2010.07109.x JOURNAL ARTICLE Miller GM The emerging role of trace amine-associated receptor 1 in the functional regulation of monoamine transporters and dopaminergic activity. J. Neurochem. 116 2 2011 164-76 378 2472386 JOURNAL ARTICLE Bayne ML, Applebaum J, Underwood D, Chicchi GG, Green BG, Hayes NS, Cascieri MA The C region of human insulin-like growth factor (IGF) I is required for high affinity binding to the type 1 IGF receptor. J. Biol. Chem. 264 19 1989 11004-8 379 NDA:021839 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021839s016lbl.pdf 2014 380 21976485 10.1073/pnas.1105787108 JOURNAL ARTICLE Van Goor F, Hadida S, Grootenhuis PD, Burton B, Stack JH, Straley KS, Decker CJ, Miller M, McCartney J, Olson ER, Wine JJ, Frizzell RA, Ashlock M, Negulescu PA Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc. Natl. Acad. Sci. U.S.A. 108 46 2011 18843-8 381 NDA:206038 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206038Orig1s000lbl.pdf 2015 382 BLA:103293 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/103293s5130lbl.pdf 2012 269 20030735 10.1111/j.1472-8206.2009.00805.x JOURNAL ARTICLE Haenisch B, Walstab J, Herberhold S, Bootz F, Tschaikin M, Ramseger R, Bönisch H Alpha-adrenoceptor agonistic activity of oxymetazoline and xylometazoline. Fundam Clin Pharmacol 24 6 2010 729-39 270 15017615 JOURNAL ARTICLE Atherton C, Jones J, McKaig B, Bebb J, Cunliffe R, Burdsall J, Brough J, Stevenson D, Bonner J, Rordorf C, Scott G, Branson J, Hawkey CJ Pharmacology and gastrointestinal safety of lumiracoxib, a novel cyclooxygenase-2 selective inhibitor: An integrated study. Clin. Gastroenterol. Hepatol. 2 2 2004 113-20 271 10794682 JOURNAL ARTICLE Talley JJ, Bertenshaw SR, Brown DL, Carter JS, Graneto MJ, Kellogg MS, Koboldt CM, Yuan J, Zhang YY, Seibert K N-[[(5-methyl-3-phenylisoxazol-4-yl)-phenyl]sulfonyl]propanamide, sodium salt, parecoxib sodium: A potent and selective inhibitor of COX-2 for parenteral administration. J. Med. Chem. 43 9 2000 1661-3 272 18060946 JOURNAL ARTICLE Attardi BJ, Zeleznik A, Simhan H, Chiao JP, Mattison DR, Caritis SN Comparison of progesterone and glucocorticoid receptor binding and stimulation of gene expression by progesterone, 17-alpha hydroxyprogesterone caproate, and related progestins. Am. J. Obstet. Gynecol. 197 6 2007 599.e1-7 273 NDA:021945 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021945s005lbl.pdf 2013 274 BLA:125031 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/125031s082lbl.pdf 2007 275 BLA:103353 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/103353s5184lbl.pdf 2015 276 20022913 10.1093/chemse/bjp092 JOURNAL ARTICLE Meyerhof W, Batram C, Kuhn C, Brockhoff A, Chudoba E, Bufe B, Appendino G, Behrens M The molecular receptive ranges of human TAS2R bitter taste receptors. Chem. Senses 35 2 2010 157-70 277 NDA:019734 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022276s003lbl.pdf 2014 278 NDA:203568 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/203568s004lbl.pdf 2015 249 NDA:022264 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022264s013s014lbl.pdf 2014 250 NDA:206619 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206619s003lbl.pdf 2015 251 NDA:021756 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021756s018lbl.pdf 2011 252 BLA:125469 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/125469Orig1s000Lbl.pdf 2014 253 NDA:206143 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206143Orig1s000lbl.pdf 2015 254 NDA:016466 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/016466s046lbl.pdf 2014 255 NDA:203214 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/203214s007lbl.pdf 2014 256 BLA:125496 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125496s000lbl.pdf 2014 257 BLA:103795 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/103795s5548lbl.pdf 2015 258 BLA:103792 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/103792s5311lbl.pdf 2014 259 NDA:020261 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020261s048,021192s021lbl.pdf 2012 260 NDA:021174 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021174s020lbl.pdf 2006 261 NDA:020986 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020986s059s081lbl.pdf 2015 262 BLA:125476 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125476s000lbl.pdf 2014 263 BLA:125486 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125486_s008lbl.pdf 2014 264 BLA:125019 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125019s210s213lbl.pdf 2013 265 EMEA/H/C/000771 DRUG LABEL http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000771/WC500020327.pdf 2014 266 NDA:021536 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021536s031s051lbl.pdf 2015 268 8950316 JOURNAL ARTICLE Uchiyama-Tsuyuki Y, Saitoh M, Muramatsu M Identification and characterization of the 5-HT4 receptor in the intestinal tract and striatum of the guinea pig. Life Sci. 59 25-26 1996 2129-37 169 8483969 JOURNAL ARTICLE Blandizzi C, Mengozzi G, Intorre L, Natale G, Soldani G, Del Tacca M Inhibitory cholinergic effects of esaprazole on gastric secretion and plasma gastrin levels in the dog. Pharmacology 46 4 1993 231-40 170 NDA:207103 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207103s000lbl.pdf 2015 171 15542782 JOURNAL ARTICLE Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E, Albassam M, Zheng X, Leopold WR, Pryer NK, Toogood PL Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol. Cancer Ther. 3 11 2004 1427-38 172 NDA:206947 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206947s000lbl.pdf 2015 173 17943726 JOURNAL ARTICLE Matsui J, Yamamoto Y, Funahashi Y, Tsuruoka A, Watanabe T, Wakabayashi T, Uenaka T, Asada M E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int. J. Cancer 122 3 2008 664-71 174 NDA:021912 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021912s013lbl.pdf 2014 176 12090787 JOURNAL ARTICLE Handley DA, Senanayake CH, Dutczak W, Benovic JL, Walle T, Penn RB, Wilkinson HS, Tanoury GJ, Andersson RG, Johansson F, Morley J Biological actions of formoterol isomers. Pulm Pharmacol Ther 15 2 2002 135-45 177 NDA:205353 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205353s000lbl.pdf 2015 178 23913691 10.1074/jbc.M113.485979 JOURNAL ARTICLE Ehmann DE, Jahic H, Ross PL, Gu RF, Hu J, Durand-Réville TF, Lahiri S, Thresher J, Livchak S, Gao N, Palmer T, Walkup GK, Fisher SL Kinetics of avibactam inhibition against Class A, C, and D β-lactamases. J. Biol. Chem. 288 39 2013 27960-71 179 EMEA/H/C/000532 DRUG LABEL http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000532/WC500040171.pdf 2015 180 NDA:200603 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/200603s015lbl.pdf 2013 181 NDA:011757 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/011757s103lbl.pdf 2014 182 25120077 10.1038/npp.2014.207 JOURNAL ARTICLE Hida H, Mouri A, Mori K, Matsumoto Y, Seki T, Taniguchi M, Yamada K, Iwamoto K, Ozaki N, Nabeshima T, Noda Y Blonanserin ameliorates phencyclidine-induced visual-recognition memory deficits: the complex mechanism of blonanserin action involving D₃-5-HT₂A and D₁-NMDA receptors in the mPFC. Neuropsychopharmacology 40 3 2015 601-13 183 NDA:021879 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021879s005lbl.pdf 2015 184 EMEA/H/C/002294 DRUG LABEL http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002294/WC500117862.pdf 2015 185 NDA:205776 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205776s000lbl.pdf 2014 186 NDA:020920 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/20920s033lbl.pdf 2013 187 BLA:125057 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125057s367lbl.pdf 2014 188 NDA:021081 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021081s062lbl.pdf 2015 189 EMEA/H/C/002548 DRUG LABEL http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002548/WC500182307.pdf 2015 190 NDA:022505 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022505s004lbl.pdf 2013 191 NDA:202057 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/202057s009lbl.pdf 2013 192 BLA:125390 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125390s004lbl.pdf 2014 193 NDA:020280 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020280s077lbl.pdf 2014 194 BLA:103948 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/103948s5139lbl.pdf 2014 195 12482421 JOURNAL ARTICLE Ohwada J, Tsukazaki M, Hayase T, Oikawa N, Isshiki Y, Fukuda H, Mizuguchi E, Sakaitani M, Shiratori Y, Yamazaki T, Ichihara S, Umeda I, Shimma N Design, synthesis and antifungal activity of a novel water soluble prodrug of antifungal triazole. Bioorg. Med. Chem. Lett. 13 2 2003 191-6 196 NDA:207500 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207500Orig1s000lbl.pdf 2015 197 BLA:125516 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125516s000lbl.pdf 2015 198 EMEA/H/C/000773 DRUG LABEL http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000773/WC500045832.pdf 2014 199 BLA:125370 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125370s053lbl.pdf 2014 200 BLA:103575 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/103575s5126lbl.pdf 2013 201 BLA:125326 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125326s060lbl.pdf 2014 202 BLA:125319 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125319s081lbl.pdf 2014 203 BLA:103749 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/103749s5059lbl.pdf 2005 204 BLA:125084 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125084s063lbl.pdf 2015 205 24936658 10.1371/journal.pone.0099440 JOURNAL ARTICLE Benod C, Villagomez R, Filgueira CS, Hwang PK, Leonard PG, Poncet-Montange G, Rajagopalan S, Fletterick RJ, Gustafsson JÅ, Webb P The human orphan nuclear receptor tailless (TLX, NR2E1) is druggable. PLoS ONE 9 6 2014 e99440 209 9112065 JOURNAL ARTICLE Hoogkamer JF, Kleinbloesem CH, Nokhodian A, Ouwerkerk MJ, Lankhaar G, Ungethüm W, Kirch W Pharmacokinetics of imidapril and its active metabolite imidaprilat following single dose and during steady state in patients with impaired liver function. Eur. J. Clin. Pharmacol. 51 6 1997 489-91 210 3000389 JOURNAL ARTICLE Takeyama K, Minato H, Fukuya F, Kawahara S, Hosoki K, Kadokawa T Antihypertensive activity of alacepril, an orally active angiotensin converting enzyme inhibitor, in renal hypertensive rats and dogs. Arzneimittelforschung 35 10 1985 1502-7 211 2419701 JOURNAL ARTICLE Holck M, Fischli W, Hefti F, Gerold M Cardiovascular effects of the new angiotensin-converting-enzyme inhibitor, cilazapril, in anesthetized and conscious dogs. J. Cardiovasc. Pharmacol. 8 1 1986 99-108 212 2484083 JOURNAL ARTICLE DeForrest JM, Waldron TL, Krapcho J, Turk C, Rubin B, Powell JR, Cushman DW, Petrillo EW Preclinical pharmacology of zofenopril, an inhibitor of angiotensin I converting enzyme. J. Cardiovasc. Pharmacol. 13 6 1989 887-94 213 8427943 JOURNAL ARTICLE Suzuki H, Kawaratani T, Shioya H, Uji Y, Saruta T Study on pharmacokinetics of a new biliary excreted oral angiotensin converting enzyme inhibitor, temocapril (CS-622) in humans. Biopharm Drug Dispos 14 1 1993 41-50 214 6782492 JOURNAL ARTICLE Schrör K, Sauerland S, Kuhn A, Rösen R Different sensitivities of prostaglandin-cyclooxygenases in blood platelets and coronary arteries against non-steroidal antiinflammatory drugs. Naunyn Schmiedebergs Arch. Pharmacol. 313 1 1980 69-76 215 BLA:125147 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125147s200lbl.pdf 2015 216 BLA:125085 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125085s305lbl.pdf 2014 217 BLA:125409 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125409s104lbl.pdf 2015 218 BLA:125377 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125377s055lbl.pdf 2015 219 BLA:125075 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/125075s130lbl.pdf 2009 220 EMEA/H/C/002498 DRUG LABEL http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002498/WC500138940.pdf 2015 221 BLA:125349 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125349s000lbl.pdf 2012 222 10.1111/j.1527-3458.1998.tb00067.x JOURNAL ARTICLE Kojima, Jun; Onodera, Kenji; Ozeki, Mitsuo; Nakayama, Kunio Ipidacrine (NIK-247): A Review of Multiple Mechanisms as an Antidementia Agent CNS Drug Reviews 4 3 1998 247-59 223 NDA:206162 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206162lbl.pdf 2014 224 9530547 JOURNAL ARTICLE Gunasekara NS, Faulds D Raltitrexed. A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer. Drugs 55 3 1998 423-35 225 11431468 JOURNAL ARTICLE Chao SH, Price DH Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo. J. Biol. Chem. 276 34 2001 31793-9 226 BLA:125388 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125388_S056S078lbl.pdf 2014 227 BLA:125320 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125320s170lbl.pdf 2015 228 BLA:125261 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125261s114lbl.pdf 2014 229 BLA:125289 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125289s094lbl.pdf 2013 230 BLA:125160 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125160s215lbl.pdf 2013 231 BLA:125166 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125166s368s380lbl.pdf 2014 232 BOOK Laurence L. Brunton & Bruce A. Chabner & Bjorn C. Knollmann Goodman and Gilman's The Pharmacological Basis of Therapeutics 0071624422 2011 233 EMEA/H/C/000666 DRUG LABEL http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000666/WC500021287.pdf 2009 234 BLA:125104 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125104s840s847s889lbl.pdf 2013 235 15869320 JOURNAL ARTICLE Cilansetron: KC 9946. Drugs R D 6 3 2005 169-73 236 NDA:202292 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202292s000lbl.pdf 2012 237 BLA:125156 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125156s106lbl.pdf 2015 238 BLA:103976 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/103976s5161lbl.pdf 2014 239 18974361 10.1124/jpet.108.145672 JOURNAL ARTICLE Perez-Reyes E, Van Deusen AL, Vitko I Molecular pharmacology of human Cav3.2 T-type Ca2+ channels: block by antihypertensives, antiarrhythmics, and their analogs. J. Pharmacol. Exp. Ther. 328 2 2009 621-7 240 1281221 JOURNAL ARTICLE Cohen CJ, Spires S, Van Skiver D Block of T-type Ca channels in guinea pig atrial cells by antiarrhythmic agents and Ca channel antagonists. J. Gen. Physiol. 100 4 1992 703-28 241 18306243 10.1002/ana.21315 JOURNAL ARTICLE LeWitt PA, Guttman M, Tetrud JW, Tuite PJ, Mori A, Chaikin P, Sussman NM "Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces ""off"" time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005)." Ann. Neurol. 63 3 2008 295-302 242 17616698 JOURNAL ARTICLE Demo SD, Kirk CJ, Aujay MA, Buchholz TJ, Dajee M, Ho MN, Jiang J, Laidig GJ, Lewis ER, Parlati F, Shenk KD, Smyth MS, Sun CM, Vallone MK, Woo TM, Molineaux CJ, Bennett MK Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res. 67 13 2007 6383-91 243 22080169 10.1007/s00280-011-1766-x JOURNAL ARTICLE Ning ZQ, Li ZB, Newman MJ, Shan S, Wang XH, Pan DS, Zhang J, Dong M, Du X, Lu XP Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity. Cancer Chemother. Pharmacol. 69 4 2012 901-9 244 11309480 JOURNAL ARTICLE Snyder JP, Nettles JH, Cornett B, Downing KH, Nogales E The binding conformation of Taxol in beta-tubulin: a model based on electron crystallographic density. Proc. Natl. Acad. Sci. U.S.A. 98 9 2001 5312-6 245 19010832 10.1158/1078-0432.CCR-08-0169 JOURNAL ARTICLE Morris PG, Fornier MN Microtubule active agents: beyond the taxane frontier. Clin. Cancer Res. 14 22 2008 7167-72 246 21466810 10.1016/j.lfs.2011.03.019 JOURNAL ARTICLE Inayoshi A, Sugimoto Y, Funahashi J, Takahashi S, Matsubara M, Kusaka H Mechanism underlying the block of human Cav3.2 T-type Ca2+ channels by benidipine, a dihydropyridine Ca2+ channel blocker. Life Sci. 88 19-20 2011 898-907 247 BLA:103772 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/103772s5370lbl.pdf 2015 248 BLA:103705 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/103705s5432lbl.pdf 2014 116 1717223 JOURNAL ARTICLE Roxatidine acetate. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic potential in peptic ulcer disease and related disorders Drugs 42 2 1991 240-60 117 24558448 10.1371/journal.pone.0088910 JOURNAL ARTICLE Long-term activation upon brief exposure to xanomleline is unique to M1 and M4 subtypes of muscarinic acetylcholine receptors PLoS ONE 9 2 2014 e88910 118 16274260 JOURNAL ARTICLE Preclinical pharmacology of bilastine, a new selective histamine H1 receptor antagonist: receptor selectivity and in vitro antihistaminic activity Drugs R D 6 6 2005 371-84 119 1620298 JOURNAL ARTICLE Therapeutic trial of cerebral vasospasm with the serine protease inhibitor, FUT-175, administered in the acute stage after subarachnoid hemorrhage Neurosurgery 30 3 1992 358-63 120 1983712 JOURNAL ARTICLE The effect of the H2-antagonist niperotidine on intragastric acidity in healthy subjects undergoing 24-hour pH-monitoring Ital J Gastroenterol 22 5 1990 291-4 121 21709094 10.1128/AAC.00833-10 JOURNAL ARTICLE In vitro spectrum of activity of finafloxacin, a novel, pH-activated fluoroquinolone, under standard and acidic conditions Antimicrob. Agents Chemother. 55 9 2011 4394-7 122 EU/3/08/554 DRUG LABEL http://www.ema.europa.eu/docs/en_GB/document_library/Orphan_designation/2009/10/WC500005871.pdf 2008 124 10878285 JOURNAL ARTICLE Allison AC, Eugui EM Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 47 2-3 2000 85-118 125 17915852 JOURNAL ARTICLE Binda C, Wang J, Pisani L, Caccia C, Carotti A, Salvati P, Edmondson DE, Mattevi A Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: safinamide and coumarin analogs. J. Med. Chem. 50 23 2007 5848-52 126 17030736 JOURNAL ARTICLE Caccia C, Maj R, Calabresi M, Maestroni S, Faravelli L, Curatolo L, Salvati P, Fariello RG Safinamide: from molecular targets to a new anti-Parkinson drug. Neurology 67 7 Suppl 2 2006 S18-23 127 NDA:022275 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022275s014lbl.pdf 2014 128 EMEA/H/C/000679 DRUG LABEL http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000679/WC500037902.pdf 2011 129 24872026 10.1158/2326-6066.CIR-14-0040 JOURNAL ARTICLE Wang C, Thudium KB, Han M, Wang XT, Huang H, Feingersh D, Garcia C, Wu Y, Kuhne M, Srinivasan M, Singh S, Wong S, Garner N, Leblanc H, Bunch RT, Blanset D, Selby MJ, Korman AJ In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer Immunol Res 2 9 2014 846-56 130 EMEA/H/C/002430 DRUG LABEL http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002430/WC500133771.pdf 2012 131 14599363 JOURNAL ARTICLE Witte DG, Cassar SC, Masters JN, Esbenshade T, Hancock AA Use of a fluorescent imaging plate reader--based calcium assay to assess pharmacological differences between the human and rat vanilloid receptor. J Biomol Screen 7 5 2002 466-75 132 NIHR HSC ID: 7234 ONLINE RESOURCE Zucapsaicin (Civamide) for episodic cluster headache http://www.hsc.nihr.ac.uk/files/downloads/2226/2524.a929981f.Zucapsaicin_Nov13.pdf 2013 133 BLA:125514 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125514lbl.pdf 2014 134 DRUG LABEL http://www.pmda.go.jp/english/service/pdf/drugs/remitch_jan2009_e.pdf 2009 135 17071817 JOURNAL ARTICLE Su S, Ohno Y, Lossin C, Hibino H, Inanobe A, Kurachi Y Inhibition of astroglial inwardly rectifying Kir4.1 channels by a tricyclic antidepressant, nortriptyline. J. Pharmacol. Exp. Ther. 320 2 2007 573-80 136 NDA:022036 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022036lbl.pdf 2010 137 2445740 JOURNAL ARTICLE Schmid-Antomarchi H, De Weille J, Fosset M, Lazdunski M The receptor for antidiabetic sulfonylureas controls the activity of the ATP-modulated K+ channel in insulin-secreting cells. J. Biol. Chem. 262 33 1987 15840-4 138 21486038 10.1021/jm101459g JOURNAL ARTICLE Bang-Andersen B, Ruhland T, Jørgensen M, Smith G, Frederiksen K, Jensen KG, Zhong H, Nielsen SM, Hogg S, Mørk A, Stensbøl TB Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J. Med. Chem. 54 9 2011 3206-21 139 NDA:204447 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204447s004lbl.pdf 2014 140 15322733 JOURNAL ARTICLE Knight AR, Misra A, Quirk K, Benwell K, Revell D, Kennett G, Bickerdike M Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch. Pharmacol. 370 2 2004 114-23 142 11716850 JOURNAL ARTICLE Sunaga Y, Gonoi T, Shibasaki T, Ichikawa K, Kusama H, Yano H, Seino S The effects of mitiglinide (KAD-1229), a new anti-diabetic drug, on ATP-sensitive K+ channels and insulin secretion: comparison with the sulfonylureas and nateglinide. Eur. J. Pharmacol. 431 1 2001 119-25 143 10742287 JOURNAL ARTICLE Gopalakrishnan M, Molinari EJ, Shieh CC, Monteggia LM, Roch JM, Whiteaker KL, Scott VE, Sullivan JP, Brioni JD Pharmacology of human sulphonylurea receptor SUR1 and inward rectifier K(+) channel Kir6.2 combination expressed in HEK-293 cells. Br. J. Pharmacol. 129 7 2000 1323-32 144 BLA:103691 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/103691s5095lbl.pdf 2011 145 NDA:020807 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/020807s011lbl.pdf 2006 146 BLA:125277 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125277s071lbl.pdf 2014 147 BLA:125431 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125431s000lbl.pdf 2014 148 15331566 JOURNAL ARTICLE Baggio LL, Huang Q, Brown TJ, Drucker DJ A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis. Diabetes 53 9 2004 2492-500 149 NDA:021289 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021289s019lbl.pdf 2014 150 NDA:021322 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21322lbl.pdf 2004 151 NDA:020367 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/20367s066lbl.pdf 2005 152 BLA:125276 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125276s092lbl.pdf 2013 153 23253932 10.1136/annrheumdis-2012-202371 JOURNAL ARTICLE Patel DD, Lee DM, Kolbinger F, Antoni C Effect of IL-17A blockade with secukinumab in autoimmune diseases. Ann. Rheum. Dis. 72 Suppl 2 2013 ii116-23 155 BLA:103770 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/103770s5185lbl.pdf 2014 156 16399882 JOURNAL ARTICLE Petroski RE, Pomeroy JE, Das R, Bowman H, Yang W, Chen AP, Foster AC Indiplon is a high-affinity positive allosteric modulator with selectivity for alpha1 subunit-containing GABAA receptors. J. Pharmacol. Exp. Ther. 317 1 2006 369-77 157 11755161 JOURNAL ARTICLE Noguchi H, Kitazumi K, Mori M, Shiba T Binding and neuropharmacological profile of zaleplon, a novel nonbenzodiazepine sedative/hypnotic. Eur. J. Pharmacol. 434 1-2 2002 21-8 158 23279183 10.1111/gtc.12022 JOURNAL ARTICLE Kitagawa D, Yokota K, Gouda M, Narumi Y, Ohmoto H, Nishiwaki E, Akita K, Kirii Y Activity-based kinase profiling of approved tyrosine kinase inhibitors. Genes Cells 18 2 2013 110-22 159 NDA:021938 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021938s027lbl.pdf 2014 160 21575866 10.1016/j.ccr.2011.04.004 JOURNAL ARTICLE Sakamoto H, Tsukaguchi T, Hiroshima S, Kodama T, Kobayashi T, Fukami TA, Oikawa N, Tsukuda T, Ishii N, Aoki Y CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell 19 5 2011 679-90 161 20163176 10.1021/jm9015526 JOURNAL ARTICLE McCauley JA, McIntyre CJ, Rudd MT, Nguyen KT, Romano JJ, Butcher JW, Gilbert KF, Bush KJ, Holloway MK, Swestock J, Wan BL, Carroll SS, DiMuzio JM, Graham DJ, Ludmerer SW, Mao SS, Stahlhut MW, Fandozzi CM, Trainor N, Olsen DB, Vacca JP, Liverton NJ Discovery of vaniprevir (MK-7009), a macrocyclic hepatitis C virus NS3/4a protease inhibitor. J. Med. Chem. 53 6 2010 2443-63 162 US 20080064681 A1 PATENT Hidaka, Hiroyoshi; Nishio, Masahiro; Sumi, Kengo THERAPEUTIC AGENT FOR TREATING GLAUCOMA 2008 163 EMEA/H/C/003906 DRUG LABEL http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003906/WC500181492.pdf 2015 164 18672868 10.1021/jm800355c JOURNAL ARTICLE Pinto-Bazurco Mendieta MA, Negri M, Jagusch C, Müller-Vieira U, Lauterbach T, Hartmann RW Synthesis, biological evaluation, and molecular modeling of abiraterone analogues: novel CYP17 inhibitors for the treatment of prostate cancer. J. Med. Chem. 51 16 2008 5009-18 165 BLA:103764 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2001/basnova032301LB.pdf 2001 166 12191614 JOURNAL ARTICLE Sasaki Y, Suzuki M, Hidaka H The novel and specific Rho-kinase inhibitor (S)-(+)-2-methyl-1-[(4-methyl-5-isoquinoline)sulfonyl]-homopiperazine as a probing molecule for Rho-kinase-involved pathway. Pharmacol. Ther. 93 2-3 2002 225-32 167 25414122 10.1007/s40265-014-0333-2 JOURNAL ARTICLE Garnock-Jones KP Ripasudil: first global approval. Drugs 74 18 2014 2211-5 168 BLA:125511 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125511s000lbl.pdf 2015 106 11830761 JOURNAL ARTICLE Lapin I Phenibut (beta-phenyl-GABA): a tranquilizer and nootropic drug. CNS Drug Rev 7 4 2001 471-81 107 NDA:020788 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020788s024lbl.pdf 2014 108 BLA:125418 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125418s020lbl.pdf 2013 109 EMEA/H/C/000916 DRUG LABEL http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000916/WC500038317.pdf 2014 110 NDA:019810 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/019810s098,022056s014lbl.pdf 2014 111 9520489 JOURNAL ARTICLE Nemeth EF, Steffey ME, Hammerland LG, Hung BC, Van Wagenen BC, DelMar EG, Balandrin MF Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc. Natl. Acad. Sci. U.S.A. 95 7 1998 4040-5 112 15200144 10.1016/j.ceca.2003.10.013 JOURNAL ARTICLE Breitwieser GE, Miedlich SU, Zhang M Calcium sensing receptors as integrators of multiple metabolic signals. Cell Calcium 35 3 2004 209-16 113 19751980 10.1016/j.bmc.2009.08.024 JOURNAL ARTICLE Aurelio L, Valant C, Figler H, Flynn BL, Linden J, Sexton PM, Christopoulos A, Scammells PJ 3- and 6-Substituted 2-amino-4,5,6,7-tetrahydrothieno[2,3-c]pyridines as A1 adenosine receptor allosteric modulators and antagonists. Bioorg. Med. Chem. 17 20 2009 7353-61 114 BLA:125477 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125477s007lbl.pdf 2014 115 24169554 10.1210/en.2013-1658 JOURNAL ARTICLE Gingell JJ, Burns ER, Hay DL Activity of pramlintide, rat and human amylin but not Aβ1-42 at human amylin receptors. Endocrinology 155 1 2014 21-6 1 BOOK Karen Baxter Stockley's Drug Interactions 0853699143 2010 2 ONLINE RESOURCE Veterans Health Administration Veterans Health Administration (VHA) National Drug File - Reference Terminology (NDF-RT) http://www.cancer.gov/cancertopics/cancerlibrary/terminologyresources/fmt 3 ONLINE RESOURCE Wolters Kluwer Health Lexicomp Online http://www.lexi.com 4 19661462 10.1161/CIRCRESAHA.109.198572 JOURNAL ARTICLE Using lidocaine and benzocaine to link sodium channel molecular conformations to state-dependent antiarrhythmic drug affinity. Circ Res 2009 5 18500680 10.1055/s-2008-1076699 JOURNAL ARTICLE Cetilistat (ATL-962), a novel pancreatic lipase inhibitor, ameliorates body weight gain and improves lipid profiles in rats. Horm Metab Res 2008 6 19428599 10.1016/j.antiviral.2009.02.198 JOURNAL ARTICLE T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections. Antiviral Res 2009 7 19783139 10.1016/j.bmcl.2009.08.091 JOURNAL ARTICLE Discovery of 3-(2-cyano-4-pyridyl)-5-(4-pyridyl)-1,2,4-triazole, FYX-051 - a xanthine oxidoreductase inhibitor for the treatment of hyperuricemia [corrected]. Bioorg Med Chem Lett 2009 8 22139434 10.1007/s00210-011-0713-z JOURNAL ARTICLE Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo. Naunyn Schmiedebergs Arch Pharmacol 2012 9 20302302 10.1021/jm901893x JOURNAL ARTICLE (1S)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucito l (TS-071) is a potent, selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for type 2 diabetes treatment. J Med Chem 2010 10 22889351 10.1021/jm300884k JOURNAL ARTICLE Discovery of tofogliflozin, a novel C-arylglucoside with an O-spiroketal ring system, as a highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem 2012 11 12519058 10.1021/jm020964w JOURNAL ARTICLE Potential tumor-selective nitroimidazolylmethyluracil prodrug derivatives: inhibitors of the angiogenic enzyme thymidine phosphorylase. J Med Chem 2003 12 22959556 10.1016/j.bmc.2012.08.012 JOURNAL ARTICLE Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-y lcarbonyl]thiazolidine): a highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Bioorg Med Chem 2012 44 20959606 10.1182/blood-2010-03-275305 JOURNAL ARTICLE CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood 2011 13 22019046 10.1016/j.bmc.2011.09.043 JOURNAL ARTICLE Discovery and pharmacological characterization of N-[2-({2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl}amino)-2-methylpropyl]-2-methyl pyrazolo[1,5-a]pyrimidine-6-carboxamide hydrochloride (anagliptin hydrochloride salt) as a potent and selective DPP-IV inhibitor. Bioorg Med Chem 2011 14 20863829 10.1016/j.ejphar.2010.09.019 JOURNAL ARTICLE Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit. Eur J Pharmacol 2010 15 20565075 10.1021/jm100541c JOURNAL ARTICLE Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H -1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomnia. J Med Chem 2010 16 25043012 10.1038/nature13527 JOURNAL ARTICLE Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide. Nature 2014 17 21502615 10.1128/AAC.01565-10 JOURNAL ARTICLE In vivo pharmacodynamics of torezolid phosphate (TR-701), a new oxazolidinone antibiotic, against methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains in a mouse thigh infection model. Antimicrob Agents Chemother 2011 18 11302816 10.1128/AAC.45.5.1493-1499.2001 JOURNAL ARTICLE In vitro antifungal activity of KP-103, a novel triazole derivative, and its therapeutic efficacy against experimental plantar tinea pedis and cutaneous candidiasis in guinea pigs. Antimicrob Agents Chemother 2001 19 20410884 10.1038/nature08960 JOURNAL ARTICLE Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 2010 20 17293563 10.1124/jpet.106.115840 JOURNAL ARTICLE Effect of (R)-2-(2-aminothiazol-4-yl)-4'-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function. J Pharmacol Exp Ther 2007 21 23742252 10.1021/jm400402q JOURNAL ARTICLE Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulf onyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials. J Med Chem 2013 22 18447380 10.1021/jm800180e JOURNAL ARTICLE Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity. J Med Chem 2008 23 22058426 10.1194/jlr.M021261 JOURNAL ARTICLE Property-based design of a glucosylceramide synthase inhibitor that reduces glucosylceramide in the brain. J Lipid Res 2012 24 23499664 10.1016/j.neuropharm.2013.02.024 JOURNAL ARTICLE Levomilnacipran (F2695), a norepinephrine-preferring SNRI: profile in vitro and in models of depression and anxiety. Neuropharmacology 2013 25 19256507 10.1021/jm900210d JOURNAL ARTICLE Discovery of (S)-N-[2-[1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihy dro-1H-isoindol-4-yl] acetamide (apremilast), a potent and orally active phosphodiesterase 4 and tumor necrosis factor-alpha inhibitor. J Med Chem 2009 26 21985634 10.1111/j.1463-1326.2011.01517.x JOURNAL ARTICLE Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab 2012 27 2164086 JOURNAL ARTICLE BY 1023/SK&F 96022 INN pantoprazole, a novel gastric proton pump inhibitor, potently inhibits acid secretion but lacks relevant cytochrome P450 interactions. J Pharmacol Exp Ther 1990 28 10454045 10.1211/0022357991772989 JOURNAL ARTICLE [3H]AL-5848 ([3H]9beta-(+)-Fluprostenol). Carboxylic acid of travoprost (AL-6221), a novel FP prostaglandin to study the pharmacology and autoradiographic localization of the FP receptor. J Pharm Pharmacol 1999 29 22640220 10.2174/187152412802430129 JOURNAL ARTICLE Melatonin and synthetic melatonergic agonists: actions and metabolism in the central nervous system. Cent Nerv Syst Agents Med Chem 2012 30 20371707 10.1124/jpet.110.167007 JOURNAL ARTICLE Pharmacological characterization of olodaterol, a novel inhaled beta2-adrenoceptor agonist exerting a 24-hour-long duration of action in preclinical models. J Pharmacol Exp Ther 2010 31 18417092 10.1016/j.ando.2008.02.022 JOURNAL ARTICLE Preclinical pharmacology of the new GLP-1 receptor agonist AVE0010. Ann Endocrinol (Paris) 2008 32 19317446 10.1021/jm801601v JOURNAL ARTICLE Discovery of novel 1-azoniabicyclo[2.2.2]octane muscarinic acetylcholine receptor antagonists. J Med Chem 2009 33 22171087 10.1124/jpet.111.189068 JOURNAL ARTICLE Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder. J Pharmacol Exp Ther 2012 34 19263460 10.1002/cmdc.200900014 JOURNAL ARTICLE Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension. ChemMedChem 2009 35 11256231 10.1358/mf.2000.22.8.701373 JOURNAL ARTICLE Comparison of inhibitory activities of donepezil and other cholinesterase inhibitors on acetylcholinesterase and butyrylcholinesterase in vitro. Methods Find Exp Clin Pharmacol 2000 36 22862294 10.1021/jm3009103 JOURNAL ARTICLE The discovery of N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-p ropylsulfamide (Macitentan), an orally active, potent dual endothelin receptor antagonist. J Med Chem 2012 37 17154430 10.1002/cmdc.200600221 JOURNAL ARTICLE Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase. ChemMedChem 2007 38 20845908 10.1021/jm100863x JOURNAL ARTICLE Discovery of a beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. J Med Chem 2010 39 18678486 10.1016/j.bmcl.2008.07.088 JOURNAL ARTICLE Structure-activity relationship study on a novel series of cyclopentane-containing macrocyclic inhibitors of the hepatitis C virus NS3/4A protease leading to the discovery of TMC435350. Bioorg Med Chem Lett 2008 40 10461840 JOURNAL ARTICLE Efficacy of NND-502, a novel imidazole antimycotic agent, in experimental models of Candida albicans and Aspergillus fumigatus infections. Int J Antimicrob Agents 1999 41 9559824 JOURNAL ARTICLE In vitro and in vivo antidermatophyte activities of NND-502, a novel optically active imidazole antimycotic agent. Antimicrob Agents Chemother 1998 42 12939461 JOURNAL ARTICLE Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. Mol Cancer Ther 2003 43 17588934 10.1126/science.1142189 JOURNAL ARTICLE An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site. Science 2007 45 23601816 10.1016/j.bmc.2013.02.058 JOURNAL ARTICLE Synthesis and biological evaluation of Esaprazole analogues showing sigma1 binding and neuroprotective properties in vitro. Bioorg Med Chem 2013 46 20503967 10.1021/jm100146h JOURNAL ARTICLE Factor Xa inhibitors: next-generation antithrombotic agents. J Med Chem 2010 47 16332435 10.1016/j.bmcl.2005.11.047 JOURNAL ARTICLE Design and synthesis of a novel, achiral class of highly potent and selective, orally active neurokinin-1 receptor antagonists. Bioorg Med Chem Lett 2006 48 24320933 10.1021/jm401499g JOURNAL ARTICLE Discovery of ledipasvir (GS-5885): a potent, once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infection. J Med Chem 2014 49 18232657 10.1021/jm701348d JOURNAL ARTICLE Lipophilic modifications to dinucleoside polyphosphates and nucleotides that confer antagonist properties at the platelet P2Y12 receptor. J Med Chem 2008 50 17872968 10.1124/mol.107.039388 JOURNAL ARTICLE The molecular basis of high-affinity binding of the antiarrhythmic compound vernakalant (RSD1235) to Kv1.5 channels. Mol Pharmacol 2007 51 10428387 10.1016/S0968-0896(99)00003-6 JOURNAL ARTICLE Synthesis and antimuscarinic activity of a series of 4-(1-Imidazolyl)-2,2-diphenylbutyramides: discovery of potent and subtype-selective antimuscarinic agents. Bioorg Med Chem 1999 52 19522465 10.1021/jm900431g JOURNAL ARTICLE Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120). J Med Chem 2009 53 18570382 10.1021/bi800438k JOURNAL ARTICLE Defining the binding site of levosimendan and its analogues in a regulatory cardiac troponin C-troponin I complex. Biochemistry 2008 54 22264484 10.1016/j.bmcl.2011.12.116 JOURNAL ARTICLE Synthesis and antihypertensive activity of pyrimidin-4(3H)-one derivatives as losartan analogue for new angiotensin II receptor type 1 (AT1) antagonists. Bioorg Med Chem Lett 2012 55 20590641 10.1111/j.1476-5381.2010.00816.x JOURNAL ARTICLE Molecular determinants of state-dependent block of voltage-gated sodium channels by pilsicainide. Br J Pharmacol 2010 56 18800822 10.1021/jm8001263 JOURNAL ARTICLE 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin- 1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1. J Med Chem 2008 57 22869577 10.1128/AAC.01186-12 JOURNAL ARTICLE Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032). Antimicrob Agents Chemother 2012 58 1830563 10.1161/01.HYP.18.1.22 JOURNAL ARTICLE Ro 42-5892 is a potent orally active renin inhibitor in primates. Hypertension 1991 59 18299583 10.1073/pnas.0708930105 JOURNAL ARTICLE Pharmacological disruption of calcium channel trafficking by the alpha2delta ligand gabapentin. Proc Natl Acad Sci U S A 2008 60 21651903 10.1016/j.ejphar.2011.05.054 JOURNAL ARTICLE Pregabalin is a potent and selective ligand for alpha(2)delta-1 and alpha(2)delta-2 calcium channel subunits. Eur J Pharmacol 2011 61 8839659 10.1007/s002280050126 JOURNAL ARTICLE Antimuscarinic effect of tiquizium bromide in vitro and in vivo. Eur J Clin Pharmacol 1996 62 24508831 10.1016/j.ejmech.2014.01.020 JOURNAL ARTICLE Synthesis, biological evaluation and molecular modeling study of novel tacrine-carbazole hybrids as potential multifunctional agents for the treatment of Alzheimer's disease. Eur J Med Chem 2014 63 2851680 10.1254/jjp.48.349 JOURNAL ARTICLE Pharmacological profiles of CS-622, a novel angiotensin converting enzyme inhibitor. Jpn J Pharmacol 1988 64 3021350 10.1248/cpb.34.2852 JOURNAL ARTICLE Design and synthesis of N-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L -alanyl]-N-(indan-2-yl)glycine (CV-3317), a new, potent angiotensin converting enzyme inhibitor. Chem Pharm Bull (Tokyo) 1986 65 8891872 10.1097/00005344-199610000-00003 JOURNAL ARTICLE Affinity of angiotensin I-converting enzyme (ACE) inhibitors for N- and C-binding sites of human ACE is different in heart, lung, arteries, and veins. J Cardiovasc Pharmacol 1996 66 12510841 10.1007/BF02977007 JOURNAL ARTICLE Mechanism of erectogenic effect of the selective phosphodiesterase type 5 inhibitor, DA-8159. Arch Pharm Res 2002 67 10976457 10.1254/fpj.116.63 JOURNAL ARTICLE [Pharmacological properties of naftopidil, a drug for treatment of the bladder outlet obstruction for patients with benign prostatic hyperplasia]. Nihon Yakurigaku Zasshi 2000 68 2572952 10.1016/0024-3205(89)90040-4 JOURNAL ARTICLE The partial opiate receptor agonists, dezocine and ciramadol act as mu receptor antagonists at the feline ileocecal sphincter. Life Sci 1989 69 19153939 JOURNAL ARTICLE A randomized, open-label trial comparing methadone and Levo-Alpha-Acetylmethadol (LAAM) in maintenance treatment of opioid addiction. Pharmacopsychiatry 2009 70 5224878 JOURNAL ARTICLE Octapressin as a vasoconstrictor in dental plexus anesthesia. Odontol Revy 1966 71 17179482 10.1093/jnci/djj498 JOURNAL ARTICLE Effect of cromolyn on S100P interactions with RAGE and pancreatic cancer growth and invasion in mouse models. J Natl Cancer Inst 2006 72 21669536 10.1016/j.bmc.2011.05.033 JOURNAL ARTICLE Mapping the intestinal alpha-glucogenic enzyme specificities of starch digesting maltase-glucoamylase and sucrase-isomaltase. Bioorg Med Chem 2011 73 17275317 10.1016/j.bmc.2007.01.014 JOURNAL ARTICLE Synthesis and structure-activity relationships of novel warfarin derivatives. Bioorg Med Chem 2007 74 6148400 10.1111/j.2042-7158.1984.tb04449.x JOURNAL ARTICLE Determination of biological activity of adinazolam and its metabolites. J Pharm Pharmacol 1984 75 10720420 10.1161/01.RES.86.5.580 JOURNAL ARTICLE The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 2000 76 1775162 10.1016/0166-6851(91)90062-B JOURNAL ARTICLE Artemisinin (qinghaosu): the role of intracellular hemin in its mechanism of antimalarial action. Mol Biochem Parasitol 1991 77 15686911 10.1016/j.bmcl.2004.12.028 JOURNAL ARTICLE Syntheses and properties of the major hydroxy metabolites in humans of blonanserin AD-5423, a novel antipsychotic agent. Bioorg Med Chem Lett 2005 78 15494035 10.1042/BST0320865 JOURNAL ARTICLE Amylin receptors: molecular composition and pharmacology. Biochem Soc Trans 2004 79 15126366 10.1158/0008-5472.CAN-03-3403 JOURNAL ARTICLE Characterization of the interaction of ingenol 3-angelate with protein kinase C. Cancer Res 2004 80 2165421 10.1016/0005-2728(90)90114-J JOURNAL ARTICLE Flux-dependent increase in the stoichiometry of charge translocation by mitochondrial ATPase/ATP synthase induced by almitrine. Biochim Biophys Acta 1990 81 23647933 10.1111/jce.12155 JOURNAL ARTICLE Dronedarone's inhibition of If current is the primary mechanism responsible for its bradycardic effect. J Cardiovasc Electrophysiol 2013 82 24400777 10.1021/jm401398x JOURNAL ARTICLE Discovery of ABT-267, a pan-genotypic inhibitor of HCV NS5A. J Med Chem 2014 83 22470110 10.1128/AAC.06283-11 JOURNAL ARTICLE Pharmacokinetic/Pharmacodynamic predictors of clinical potency for hepatitis C virus nonnucleoside polymerase and protease inhibitors. Antimicrob Agents Chemother 2012 84 24102143 10.1111/bph.12408 JOURNAL ARTICLE Characterization of molecular and cellular functions of the cyclin-dependent kinase CDK9 using a novel specific inhibitor. Br J Pharmacol 2014 85 9347318 10.1016/S0306-3623(97)00258-9 JOURNAL ARTICLE Antagonistic effects of isofloxythepin on dopamine D1 and D2 receptors and behaviors in rats. Gen Pharmacol 1997 86 24786236 10.1038/aps.2013.202 JOURNAL ARTICLE Inhibitory effects of phytochemicals on metabolic capabilities of CYP2D6(*)1 and CYP2D6(*)10 using cell-based models in vitro. Acta Pharmacol Sin 2014 87 12388666 10.1124/jpet.102.039867 JOURNAL ARTICLE Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther 2002 88 2907502 10.1254/fpj.92.181 JOURNAL ARTICLE Pharmacological investigation of bezafibrate, a hypolipidemic agent. II. Mechanism of the hypolipidemic action of bezafibrate in rats Nihon Yakurigaku Zasshi 92 3 1988 89 4396765 JOURNAL ARTICLE A comparison of the effects of noradrenaline, adrenaline and some phenylephrine derivatives on alpha-, beta- and beta- adrenergic receptors S Afr Med J 45 10 1971 90 23859232 10.3109/02770903.2013.823447 JOURNAL ARTICLE A review on leukotrienes and their receptors with reference to asthma J Asthma 50 9 2013 91 23928358 10.1074/jbc.M113.457119 JOURNAL ARTICLE VKORC1L1, an enzyme rescuing the vitamin K 2,3-epoxide reductase activity in some extrahepatic tissues during anticoagulation therapy J Biol Chem 288 40 2013 92 17877367 10.1021/bi700125e JOURNAL ARTICLE Molecular identification of the human melanocortin-2 receptor responsible for ligand binding and signaling Biochemistry 46 40 2007 93 23319593 10.1074/jbc.M112.412130 JOURNAL ARTICLE Hydralazine and organic nitrates restore impaired excitation-contraction coupling by reducing calcium leak associated with nitroso-redox imbalance J Biol Chem 288 9 2013 94 19466525 10.1007/s00380-008-1106-1 JOURNAL ARTICLE Effect of edaravone, a novel free radical scavenger, supplemented to cardioplegia on myocardial function after cardioplegic arrest: in vitro study of isolated rat heart Heart Vessels 24 3 2009 95 502-P ONLINE RESOURCE LC15-0444 is a Novel, Potent, Selective, and Orally Active Dipeptidyl Peptidase IV Inhibitor http://professional.diabetes.org/Content/Posters/2008/p502-P.pdf 2008 96 10427 JOURNAL ARTICLE Harms HH Isoproterenol antagonism of cardioselective beta adrenergic receptor blocking agents: a comparative study of human and guinea-pig cardiac and bronchial beta adrenergic receptors J Pharmacol Exp Ther 199 2 1976 97 23393163 10.1124/mol.112.081935 JOURNAL ARTICLE Vesnarinone suppresses TNFalpha mRNA expression by inhibiting valosin-containing protein Mol Pharmacol 83 5 2013 98 8405122 JOURNAL ARTICLE Ca2+(-)dependent and Ca2+(-)independent vasorelaxation induced by cardiotonic phosphodiesterase inhibitors Eur J Pharmacol 240 1 1993 99 15212190 JOURNAL ARTICLE Clinical evaluation of a transdermal therapeutic system of the beta2-agonist tulobuterol in patients with mild or moderate persistent bronchial asthma Arzneimittelforschung 54 5 2004 100 20800AMZ00077000 DRUG LABEL Coretec Injection 5 mg http://eisai.jp/medical/products/di/EPI/COR_A_EPI.pdf 2009 102 BLA:125557 DRUG LABEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125557lbl.pdf 2014 103 10364735 10.1159/000029379 JOURNAL ARTICLE Reproterol: beta-2-agonist, theophylline, or both? Respiration 66 3 1999 104 22037378 10.1038/nbt.1990 JOURNAL ARTICLE Comprehensive analysis of kinase inhibitor selectivity Nat Biotechnol 29 11 2011 2708 NDA:212862 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212862s000lbl.pdf 2019 2709 NDA:212725 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212725s000lbl.pdf 2019 2710 27003761 10.1021/acs.jmedchem.6b00064 JOURNAL ARTICLE Menichincheri M, Ardini E, Magnaghi P, Avanzi N, Banfi P, Bossi R, Buffa L, Canevari G, Ceriani L, Colombo M, Corti L, Donati D, Fasolini M, Felder E, Fiorelli C, Fiorentini F, Galvani A, Isacchi A, Borgia AL, Marchionni C, Nesi M, Orrenius C, Panzeri A, Pesenti E, Rusconi L, Saccardo MB, Vanotti E, Perrone E, Orsini P Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor J Med Chem 59 7 2016 3392-3408 2711 NDA:211675 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211675s000lbl.pdf 2019 2712 30886973 10.1186/s41927-018-0031-x JOURNAL ARTICLE Parmentier JM, Voss J, Graff C, Schwartz A, Argiriadi M, Friedman M, Camp HS, Padley RJ, George JS, Hyland D, Rosebraugh M, Wishart N, Olson L, Long AJ In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494) BMC Rheumatology 2 23 2018 2713 NDA:212327 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212327s000lbl.pdf 2019 2714 18394554 10.1016/j.ccr.2008.02.009 JOURNAL ARTICLE Wernig G, Kharas MG, Okabe R, Moore SA, Leeman DS, Cullen DE, Gozo M, McDowell EP, Levine RL, Doukas J, Mak CC, Noronha G, Martin M, Ko YD, Lee BH, Soll RM, Tefferi A, Hood JD, Gilliland DG Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell 13 4 2008 311-320 2715 NDA:210828 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210828s000lbl.pdf 2019 2716 28495802 10.1152/ajpgi.00044.2017 JOURNAL ARTICLE Yin J, Tse CM, Cha B, Sarker R, Zhu XC, Walentinsson A, Greasley PJ, Donowitz M A common NHE3 single-nucleotide polymorphism has normal function and sensitivity to regulatory ligands Am J Physiol Gastrointest Liver Physiol 313 2 2017 G129-G137 2717 NDA:211801 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211801s000lbl.pdf 2019 2718 29706423 10.1016/j.bmcl.2018.04.036 JOURNAL ARTICLE Thoreau E, Arlabosse JM, Bouix-Peter C, Chambon S, Chantalat L, Daver S, Dumais L, Duvert G, Feret A, Ouvry G, Pascau J, Raffin C, Rodeville N, Soulet C, Tabet S, Talano S, Portal T Structure-based design of Trifarotene (CD5789), a potent and selective RARγ agonist for the treatment of acne Bioorg Med Chem Lett 28 10 2018 1736-1741 2719 20855361 10.1177/0333102410370873 JOURNAL ARTICLE Nelson DL, Phebus LA, Johnson KW, Wainscott DB, Cohen ML, Calligaro DO, Xu YC Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan Cephalalgia 30 10 2010 1159-1169 2720 NDA:213217 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/213217s000lbl.pdf 2019 2721 31381333 10.1021/acs.jmedchem.9b00687 JOURNAL ARTICLE Guo Y, Liu Y, Hu N, Yu D, Zhou C, Shi G, Zhang B, Wei M, Liu J, Luo L, Tang Z, Song H, Guo Y, Liu X, Su D, Zhang S, Song X, Zhou X, Hong Y, Chen S, Cheng Z, Young S, Wei Q, Wang H, Wang Q, Lv L, Wang F,Xu H, Sun H, Xing H, Li N, Zhang W, Wang Z, Liu G, Sun Z, Zhou D, Li W, Liu L, Wang L, Wang Z Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase J Med Chem 62 17 2019 7923-7940 2722 NDA:212194 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/0212194s000lbl.pdf 2019 2723 NDA:213137 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/213137s000lbl.pdf 2019 2724 27378309 10.1111/bjh.14214 JOURNAL ARTICLE Oksenberg D, Dufu K, Patel MP, Chuang C, Li Z, Xu Q, Silva-Garcia A, Zhou C, Hutchaleelaha A, Patskovska L, Patskovsky Y, Almo SC, Sinha U, Metcalf BW, Archer DR GBT440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half-life in a murine model of sickle cell disease Br J Haematol 175 1 2016 141-153 2725 NDA:211970 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211970s000lbl.pdf 2019 2726 NDA:209500 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209500s000lbl.pdf 2019 2727 NDA:212028 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212028s000lbl.pdf 2019 2728 NDA:211765 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211765s000lbl.pdf 2019 2729 BLA:761062 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761062s000lbl.pdf 2019 2730 BLA:761125 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761125s000lbl.pdf 2019 2731 BLA:761136 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761136lbl.pdf 2019 2732 24658078 10.1038/nm.3512 JOURNAL ARTICLE Suragani RN, Cadena SM, Cawley SM, Sako D, Mitchell D, Li R, Davies MV, Alexander MJ, Devine M, Loveday KS, Underwood KW, Grinberg AV, Quisel JD, Chopra R, Pearsall RS, Seehra J, Kumar R Transforming growth factor-beta superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis Nat Med 20 4 2014 408-414 2734 BLA:761128 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761128s000lbl.pdf 2019 2735 BLA:761137 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761137s000lbl.pdf 2019 2736 27013195 10.1158/0008-5472.CAN-15-1313 JOURNAL ARTICLE Challita-Eid PM, Satpayev D, Yang P, An Z, Morrison K, Shostak Y, Raitano A, Nadell R, Liu W, Lortie DR, Capo L, Verlinsky A, Leavitt M, Malik F, Avina H, Guevara CI, Dinh N, Karki S, Anand BS, Pereira DS, Joseph IB, Doñate F, Morrison K, Stover DR Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models Cancer Res 76 10 2016 3003-3013 2737 BLA:761139 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761139s000lbl.pdf 2019 2738 27026201 10.1158/1078-0432.CCR-15-2822 JOURNAL ARTICLE Ogitani Y, Aida T, Hagihara K, Yamaguchi J, Ishii C, Harada N, Soma M, Okamoto H, Oitate M, Arakawa S, Hirai T, Atsumi R, Nakada T, Hayakawa I, Abe Y, Agatsuma T DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1 Clin Cancer Res 22 20 2016 5097-5108 2739 EMEA/H/C/004587 DRUG LABEL https://www.ema.europa.eu/en/documents/product-information/nuceiva-epar-product-information_en.pdf 2019 2740 27412122 10.1007/s40265-016-0618-8 JOURNAL ARTICLE Markham A Atezolizumab: First Global Approval Drugs 76 12 2016 1227-1232 2741 30805897 10.1007/s40265-019-01077-1 JOURNAL ARTICLE Dhillon S Roxadustat: First Global Approval Drugs 79 5 2019 563-572 2742 NDA:212273 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212273s000lbl.pdf 2019 2743 29856623 10.1021/acs.jmedchem.8b00549 JOURNAL ARTICLE Wu Y, Jiang Z, Li Z, Gu J, You Q, Zhang X Click Chemistry-Based Discovery of [3-Hydroxy-5-(1 H-1,2,3-triazol-4-yl)picolinoyl]glycines as Orally Active Hypoxia-Inducing Factor Prolyl Hydroxylase Inhibitors with Favorable Safety Profiles for the Treatment of Anemia J Med Chem 61 12 2018 5332-5349 2744 NDA:211672 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211672s000,211673s000lbl.pdf 2019 2745 29061741 10.1128/AAC.01454-17 JOURNAL ARTICLE Ito A, Sato T, Ota M, Takemura M, Nishikawa T, Toba S, Kohira N, Miyagawa S, Ishibashi N, Matsumoto S, Nakamura R, Tsuji M, Yamano Y In Vitro Antibacterial Properties of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacteria Antimicrob Agents Chemother 62 1 2017 e01454-17 2746 NDA:209445 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209445s000lbl.pdf 2019 2747 NDA:206488 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/206488lbl.pdf 2019 2748 8103915 10.1038/365160a0 JOURNAL ARTICLE Blasi J, Chapman ER, Link E, Binz T, Yamasaki S, De Camilli P, Sudhof TC, Niemann H, Jahn R Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25 Nature 365 6442 1993 160-163 3082 NDA:214103 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214103lbl.pdf 2020 3083 BLA:761150 review DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/761150Orig1s000MultidisciplineR.pdf 2020 3084 EMEA/H/C/004854 report DRUG LABEL https://www.ema.europa.eu/en/documents/assessment-report/hepcludex-epar-public-assessment-report_en.pdf 2020 3085 000237990 DRUG LABEL https://www.pmda.go.jp/files/000237990.pdf 2020 3086 NDA:206966 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/206966lbl.pdf 2020 3087 8035423 10.1021/jm00040a008 JOURNAL ARTICLE Rosowsky A, Bader H, Wright JE, Keyomarsi K, Matherly LH Synthesis and biological activity of N omega-hemiphthaloyl-alpha,omega- diaminoalkanoic acid analogues of aminopterin and 3',5-dichloroaminopterin J Med Chem 37 14 1994 2167-2174 3088 21118657 10.1503/jpn.100057 JOURNAL ARTICLE Dean O, Giorlando F, Berk M N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action J Psychiatry Neurosci 36 2 2011 78-86 3187 NDA:18603 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/18603s19lbl.pdf 1998 3188 23832378 10.1007/s00210-013-0901-0 JOURNAL ARTICLE Fischer F, Vonderlin N, Zitron E, Seyler C, Scherer D, Becker R, Katus HA, Scholz EP Inhibition of cardiac Kv1.5 and Kv4.3 potassium channels by the class Ia anti-arrhythmic ajmaline: mode of action Naunyn Schmiedebergs Arch Pharmacol 386 11 2013 991-999 3189 EMEA/MRL/555/99-FINAL DRUG LABEL https://www.ema.europa.eu/en/documents/mrl-report/albendazole-oxide-summary-report-2-committee-veterinary-medicinal-products_en.pdf 1999 3190 20167843 10.1124/jpet.109.163329 JOURNAL ARTICLE Doughty-Shenton D, Joseph JD, Zhang J, Pagliarini DJ, Kim Y, Lu D, Dixon JE, Casey PJ Pharmacological targeting of the mitochondrial phosphatase PTPMT1 J Pharmacol Exp Ther 333 2 2010 584-592 3191 22981367 10.1016/j.tips.2012.08.003 JOURNAL ARTICLE Skolnick P Anxioselective anxiolytics: on a quest for the Holy Grail Trends Pharmacol Sci 33 11 2012 611-620 3192 NDA:214377 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214377s000lbl.pdf 2021 3193 28557445 10.1021/acs.jmedchem.7b00449 JOURNAL ARTICLE Follmann M, Ackerstaff J, Redlich G, Wunder F, Lang D, Kern A, Fey P, Griebenow N, Kroh W, Becker-Pelster EM, Kretschmer A, Geiss V, Li V, Straub A, Mittendorf J, Jautelat R, Schirok H, Schlemmer KH, Lustig K, Gerisch M, Knorr A, Tinel H, Mondritzki T, Trubel H, Sandner P, Stasch JP Discovery of the soluble guanylate cyclase stimulator vericiguat (BAY 1021189) for the treatment of chronic heart failure J Med Chem 60 12 2017 5146-5161 3194 NDA:212887 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212887s000lbl.pdf 2021 3195 NDA:213176 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213176s000lbl.pdf 2021 3196 29475723 10.1016/S1470-2045(18)30082-2 JOURNAL ARTICLE Burris HA 3rd, Flinn IW, Patel MR, Fenske TS, Deng C, Brander DM, Gutierrez M, Essell JH, Kuhn JG, Miskin HP, Sportelli P, Weiss MS, Vakkalanka S, Savona MR, O'Connor OA Umbralisib, a novel PI3Kdelta and casein kinase-1epsilon inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study Lancet Oncol 19 4 2018 486-496 3197 NDA:214200 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214200s000lbl.pdf 2021 3198 NDA:214200 review DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214200Orig1s000PharmR.pdf 2021 3199 NDA:213026 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213026lbl.pdf 2021 3200 NDA:214018 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214018s000lbl.pdf 2021 3201 NDA:214383 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214383s000lbl.pdf 2021 3202 NDA:213498 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213498s000lbl.pdf 2021 3203 20446681 10.1021/jm100181s JOURNAL ARTICLE Bolli MH, Abele S, Binkert C, Bravo R, Buchmann S, Bur D, Gatfield J, Hess P, Kohl C, Mangold C, Mathys B, Menyhart K, Muller C, Nayler O, Scherz M, Schmidt G, Sippel V, Steiner B, Strasser D, Treiber A, Weller T 2-Imino-thiazolidin-4-one derivatives as potent, orally active S1P1 receptor agonists J Med Chem 53 10 2010 4198-4211 3204 NDA:214231 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214231s000lbl.pdf 2021 3205 NDA:214231 review DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214231Orig1s000PharmR.pdf 2021 3206 NDA:211964 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211964s000lbl.pdf 2021 3207 NDA:211964 review DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/211964Orig1s000IntegratedR.pdf 2021 3208 BLA:761181 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761181s000lbl.pdf 2021 3210 NDA:214154 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214154s000lbl.pdf 2021 3211 18464023 10.1080/13697130802073425 JOURNAL ARTICLE Coelingh Bennink HJ, Holinka CF, Diczfalusy E Estetrol review: profile and potential clinical applications Climacteric 11 1 2008 47-58 3212 BLA:761174 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761174s000lbl.pdf 2021 3213 32134960 10.1371/journal.pone.0229206 JOURNAL ARTICLE Brown ME, Bedinger D, Lilov A, Rathanaswami P, Vásquez M, Durand S, Wallace-Moyer I, Zhong L, Nett JH, Burnina I, Caffry I, Lynaugh H, Sinclair M, Sun T, Bukowski J, Xu Y, Abdiche YN Assessing the binding properties of the anti-PD-1 antibody landscape using label-free biosensors PLoS One 15 3 2020 e0229206 3214 BLA:761196 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761196s000lbl.pdf 2021 3215 EUA:143603 DRUG LABEL https://www.fda.gov/media/143603/download 2021 3218 EUA:145802 DRUG LABEL https://www.fda.gov/media/145802/download 2021 3219 EUA:145611 DRUG LABEL https://www.fda.gov/media/145611/download 2021 3220 NDA:215014 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215014s000lbl.pdf 2021 3221 24497537 10.1182/blood-2013-11-536573 JOURNAL ARTICLE Risitano AM, Ricklin D, Huang Y, Reis ES, Chen H, Ricci P, Lin Z, Pascariello C, Raia M, Sica M, Del Vecchio L, Pane F, Lupu F, Notaro R, Resuello RR, DeAngelis RA, Lambris JD Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria Blood 123 13 2014 2094-2101 3222 NDA:214793 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214793s000lbl.pdf 2021 3223 NDA:214622 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214622s000lbl.pdf 2021 3224 NDA:213378 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213378s000lbl.pdf 2021 3225 NDA:214665 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214665s000lbl.pdf 2021 3226 NDA:214900 DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214900s000lbl.pdf 2021 3227 24323472 10.1128/AAC.02145-13 JOURNAL ARTICLE Jimenez-Ortigosa C, Paderu P, Motyl MR, Perlin DS Enfumafungin derivative MK-3118 shows increased in vitro potency against clinical echinocandin-resistant Candida Species and Aspergillus species isolates Antimicrob Agents Chemother 58 2 2014 1248-1251 3209 BLA:761181 review DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/761181Orig1s000PharmR.pdf 2021